{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T23:24:31Z","timestamp":1793316271639,"version":"4.5.0"},"reference-count":219,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T00:00:00Z","timestamp":1787702400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T00:00:00Z","timestamp":1787702400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neurooncol"],"published-print":{"date-parts":[[2026,9]]},"abstract":"Abstract<\/jats:title>\n \n Purpose<\/jats:title>\n Glioblastoma, IDH-wildtype, is characterized by diffuse invasion, profound immunosuppression, treatment resistance, and near-inevitable recurrence. Although canonical genetic alterations establish malignant capacity, they do not fully explain how glioblastoma cells adapt to hypoxic, perivascular, invasive, immunosuppressive, metabolically constrained, and treatment-injured microenvironments. We examined how chemokine signaling contributes to these adaptive behaviors.<\/jats:p>\n <\/jats:sec>\n \n Methods<\/jats:title>\n We used the hallmarks of cancer as an organizing framework to synthesize preclinical, translational, and clinical evidence on chemokine circuits in glioblastoma. We evaluated recurrent mechanistic pathways, distinguished causal functions from context-dependent biomarker associations, and assessed their therapeutic relevance.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n Chemokines act primarily as spatial and stress-responsive regulators rather than initiating oncogenic drivers. Recurrent circuits include CXCL12\u2013CXCR4 in vascular repair, invasion, and stem-like persistence; CCL2 and CCL7 signaling through CCR2 in suppressive myeloid recruitment and metabolic\u2013immune remodeling; CCL5\u2013CCR5 in perivascular protection, invasion, and DNA-damage tolerance; and CXCL8 signaling through CXCR1 and CXCR2 in angiogenesis, immune evasion, and therapy-induced plasticity. Most chemokine-directed strategies remain preclinical or early translational.<\/jats:p>\n <\/jats:sec>\n \n Conclusion<\/jats:title>\n Therapeutic development should prioritize biomarker-defined dependencies and appropriately timed combinations that disrupt selected chemokine-dependent interactions within specific biological and treatment contexts. Clinical translation will require verification of target engagement, disruption of the relevant cellular interactions, and evidence that chemokine modulation improves treatment response or delays recurrence.<\/jats:p>\n <\/jats:sec>","DOI":"10.1007\/s11060-026-05768-0","type":"journal-article","created":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T05:26:39Z","timestamp":1787721999000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["The intersection of chemokine signaling with the hallmarks of cancer in glioblastoma"],"prefix":"10.1007","volume":"179","author":[{"given":"Rafal","family":"Chojak","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jillyn R","family":"Turunen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noah B","family":"Drewes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lara","family":"Koutah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jawad","family":"Fares","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca X","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruochen","family":"Du","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Umme H","family":"Faisal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hasaan A","family":"Kazi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clare","family":"Kelley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason","family":"Miska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy B","family":"Heimberger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atique U","family":"Ahmed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maciej S.","family":"Lesniak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,26]]},"reference":[{"key":"5768_CR1","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.1038\/nature07385","volume":"455","author":"R McLendon","year":"2008","unstructured":"McLendon R, Friedman A, Bigner D, Van Meir EG, Brat DJ, Mastrogianakis M (2008) Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nat Nat Publishing Group 455:1061\u20131068. https:\/\/doi.org\/10.1038\/nature07385","journal-title":"Nat Nat Publishing Group"},{"key":"5768_CR2","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1016\/j.ccr.2009.12.020","volume":"17","author":"RGW Verhaak","year":"2010","unstructured":"Verhaak RGW, Hoadley KA, Purdom E, Wang V, Qi Y, Wilkerson MD et al (2010) Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell 17:98\u2013110. https:\/\/doi.org\/10.1016\/j.ccr.2009.12.020","journal-title":"Cancer Cell"},{"key":"5768_CR3","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1016\/j.cell.2013.09.034","volume":"155","author":"CW Brennan","year":"2013","unstructured":"Brennan CW, Verhaak RGW, McKenna A, Campos B, Noushmehr H, Salama SR et al (2013) The Somatic Genomic Landscape of Glioblastoma. Cell 155:462\u2013477. https:\/\/doi.org\/10.1016\/j.cell.2013.09.034","journal-title":"Cell"},{"key":"5768_CR4","doi-asserted-by":"publisher","unstructured":"Killela PJ, Reitman ZJ, Jiao Y, Bettegowda C, Agrawal N, Diaz LA et al (2013) TERT promoter mutations occur frequently in gliomas and a subset of tumors derived from cells with low rates of self-renewal. Proceedings of the National Academy of Sciences. Proceedings of the National Academy of Sciences.110:6021\u20136. https:\/\/doi.org\/10.1073\/pnas.1303607110","DOI":"10.1073\/pnas.1303607110"},{"key":"5768_CR5","doi-asserted-by":"publisher","first-page":"931","DOI":"10.1007\/s00401-013-1163-0","volume":"126","author":"N Nonoguchi","year":"2013","unstructured":"Nonoguchi N, Ohta T, Oh J-E, Kim Y-H, Kleihues P, Ohgaki H (2013) TERT promoter mutations in primary and secondary glioblastomas. Acta Neuropathol 126:931\u2013937. https:\/\/doi.org\/10.1007\/s00401-013-1163-0","journal-title":"Acta Neuropathol"},{"key":"5768_CR6","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1056\/NEJMoa043330","volume":"352","author":"R Stupp","year":"2005","unstructured":"Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJB et al (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352:987\u2013996. https:\/\/doi.org\/10.1056\/NEJMoa043330","journal-title":"N Engl J Med"},{"key":"5768_CR7","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1056\/NEJMoa043331","volume":"352","author":"ME Hegi","year":"2005","unstructured":"Hegi ME, Diserens A-C, Gorlia T, Hamou M-F, de Tribolet N, Weller M et al (2005) MGMT Gene Silencing and Benefit from Temozolomide in Glioblastoma. New Engl J Med Mass Med Soc 352:997\u20131003. https:\/\/doi.org\/10.1056\/NEJMoa043331","journal-title":"New Engl J Med Mass Med Soc"},{"key":"5768_CR8","doi-asserted-by":"publisher","first-page":"2038","DOI":"10.1158\/1078-0432.CCR-06-2149","volume":"13","author":"DP Cahill","year":"2007","unstructured":"Cahill DP, Levine KK, Betensky RA, Codd PJ, Romany CA, Reavie LB et al (2007) Loss of the mismatch repair protein MSH6 in human glioblastomas is associated with tumor progression during temozolomide treatment. Clin Cancer Res 13:2038\u20132045. https:\/\/doi.org\/10.1158\/1078-0432.CCR-06-2149","journal-title":"Clin Cancer Res"},{"key":"5768_CR9","doi-asserted-by":"publisher","first-page":"4622","DOI":"10.1158\/1078-0432.CCR-08-3012","volume":"15","author":"S Yip","year":"2009","unstructured":"Yip S, Miao J, Cahill DP, Iafrate AJ, Aldape K, Nutt CL et al (2009) MSH6 mutations arise in glioblastomas during temozolomide therapy and mediate temozolomide resistance. Clin Cancer Res 15:4622\u20134629. https:\/\/doi.org\/10.1158\/1078-0432.CCR-08-3012","journal-title":"Clin Cancer Res"},{"key":"5768_CR10","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1056\/NEJMoa0808710","volume":"360","author":"H Yan","year":"2009","unstructured":"Yan H, Parsons DW, Jin G, McLendon R, Rasheed BA, Yuan W et al (2009) IDH1 and IDH2 mutations in gliomas. N Engl J Med 360:765\u2013773. https:\/\/doi.org\/10.1056\/NEJMoa0808710","journal-title":"N Engl J Med"},{"key":"5768_CR11","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1007\/s00401-018-1913-0","volume":"136","author":"DJ Brat","year":"2018","unstructured":"Brat DJ, Aldape K, Colman H, Holland EC, Louis DN, Jenkins RB et al (2018) cIMPACT-NOW update 3: recommended diagnostic criteria for Diffuse astrocytic glioma, IDH-wildtype, with molecular features of glioblastoma, WHO grade IV. Acta Neuropathol 136:805\u2013810. https:\/\/doi.org\/10.1007\/s00401-018-1913-0","journal-title":"Acta Neuropathol"},{"key":"5768_CR12","doi-asserted-by":"publisher","first-page":"1231","DOI":"10.1093\/neuonc\/noab106","volume":"23","author":"DN Louis","year":"2021","unstructured":"Louis DN, Perry A, Wesseling P, Brat DJ, Cree IA, Figarella-Branger D et al (2021) The 2021 WHO Classification of Tumors of the Central Nervous System: a summary. Neuro Oncol 23:1231\u20131251. https:\/\/doi.org\/10.1093\/neuonc\/noab106","journal-title":"Neuro Oncol"},{"key":"5768_CR13","doi-asserted-by":"publisher","first-page":"920","DOI":"10.1158\/0008-5472.can-03-2073","volume":"64","author":"DJ Brat","year":"2004","unstructured":"Brat DJ, Castellano-Sanchez AA, Hunter SB, Pecot M, Cohen C, Hammond EH et al (2004) Pseudopalisades in glioblastoma are hypoxic, express extracellular matrix proteases, and are formed by an actively migrating cell population. Cancer Res 64:920\u2013927. https:\/\/doi.org\/10.1158\/0008-5472.can-03-2073","journal-title":"Cancer Res"},{"key":"5768_CR14","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1016\/j.ccr.2009.03.018","volume":"15","author":"Z Li","year":"2009","unstructured":"Li Z, Bao S, Wu Q, Wang H, Eyler C, Sathornsumetee S et al (2009) Hypoxia-Inducible Factors Regulate Tumorigenic Capacity of Glioma Stem Cells. Cancer Cell 15:501\u2013513. https:\/\/doi.org\/10.1016\/j.ccr.2009.03.018","journal-title":"Cancer Cell"},{"key":"5768_CR15","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.ccr.2006.11.020","volume":"11","author":"C Calabrese","year":"2007","unstructured":"Calabrese C, Poppleton H, Kocak M, Hogg TL, Fuller C, Hamner B et al (2007) A perivascular niche for brain tumor stem cells. Cancer Cell 11:69\u201382. https:\/\/doi.org\/10.1016\/j.ccr.2006.11.020","journal-title":"Cancer Cell"},{"key":"5768_CR16","doi-asserted-by":"publisher","first-page":"4196","DOI":"10.1038\/ncomms5196","volume":"5","author":"S Watkins","year":"2014","unstructured":"Watkins S, Robel S, Kimbrough IF, Robert SM, Ellis-Davies G, Sontheimer H (2014) Disruption of astrocyte\u2013vascular coupling and the blood\u2013brain barrier by invading glioma cells. Nat Commun Nat Publishing Group 5:4196. https:\/\/doi.org\/10.1038\/ncomms5196","journal-title":"Nat Commun Nat Publishing Group"},{"key":"5768_CR17","doi-asserted-by":"publisher","first-page":"1399","DOI":"10.1016\/j.celrep.2017.10.030","volume":"21","author":"S Darmanis","year":"2017","unstructured":"Darmanis S, Sloan SA, Croote D, Mignardi M, Chernikova S, Samghababi P et al (2017) Single-Cell RNA-Seq Analysis of Infiltrating Neoplastic Cells at the Migrating Front of Human Glioblastoma. Cell Rep 21:1399\u20131410. https:\/\/doi.org\/10.1016\/j.celrep.2017.10.030","journal-title":"Cell Rep"},{"key":"5768_CR18","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1038\/nature05236","volume":"444","author":"S Bao","year":"2006","unstructured":"Bao S, Wu Q, McLendon RE, Hao Y, Shi Q, Hjelmeland AB et al (2006) Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nat Nat Publishing Group 444:756\u2013760. https:\/\/doi.org\/10.1038\/nature05236","journal-title":"Nat Nat Publishing Group"},{"key":"5768_CR19","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1038\/nature11287","volume":"488","author":"J Chen","year":"2012","unstructured":"Chen J, Li Y, Yu T-S, McKay RM, Burns DK, Kernie SG et al (2012) A restricted cell population propagates glioblastoma growth after chemotherapy. Nature 488:522\u2013526. https:\/\/doi.org\/10.1038\/nature11287","journal-title":"Nature"},{"key":"5768_CR20","doi-asserted-by":"publisher","first-page":"13934","DOI":"10.1038\/s41598-021-93441-z","volume":"11","author":"R Chojak","year":"2021","unstructured":"Chojak R, Ko\u017aba-Goszty\u0142a M, S\u0142ychan K, Gajos D, Kotas M, Tyliszczak M et al (2021) Impact of surgical resection of butterfly glioblastoma on survival: a meta-analysis based on comparative studies. Sci Rep 11:13934. https:\/\/doi.org\/10.1038\/s41598-021-93441-z","journal-title":"Sci Rep"},{"key":"5768_CR21","doi-asserted-by":"publisher","first-page":"5671","DOI":"10.1158\/0008-5472.CAN-16-0144","volume":"76","author":"AL Chang","year":"2016","unstructured":"Chang AL, Miska J, Wainwright DA, Dey M, Rivetta CV, Yu D et al (2016) CCL2 Produced by the Glioma Microenvironment Is Essential for the Recruitment of Regulatory T Cells and Myeloid-Derived Suppressor Cells. Cancer Res 76:5671\u20135682. https:\/\/doi.org\/10.1158\/0008-5472.CAN-16-0144","journal-title":"Cancer Res"},{"key":"5768_CR22","doi-asserted-by":"publisher","first-page":"7079","DOI":"10.1158\/0008-5472.CAN-13-1355","volume":"73","author":"DW Infanger","year":"2013","unstructured":"Infanger DW, Cho Y, Lopez BS, Mohanan S, Liu SC, Gursel D et al (2013) Glioblastoma stem cells are regulated by interleukin-8 signaling in a tumoral perivascular niche. Cancer Res 73:7079\u20137089. https:\/\/doi.org\/10.1158\/0008-5472.CAN-13-1355","journal-title":"Cancer Res"},{"key":"5768_CR23","doi-asserted-by":"publisher","first-page":"1221","DOI":"10.1038\/labinvest.3700482","volume":"86","author":"D Zagzag","year":"2006","unstructured":"Zagzag D, Lukyanov Y, Lan L, Ali MA, Esencay M, Mendez O et al (2006) Hypoxia-inducible factor 1 and VEGF upregulate CXCR4 in glioblastoma: implications for angiogenesis and glioma cell invasion. Lab Invest Nat Publishing Group 86:1221\u20131232. https:\/\/doi.org\/10.1038\/labinvest.3700482","journal-title":"Lab Invest Nat Publishing Group"},{"key":"5768_CR24","doi-asserted-by":"publisher","first-page":"83701","DOI":"10.18632\/oncotarget.13295","volume":"7","author":"VN Yadav","year":"2016","unstructured":"Yadav VN, Zamler D, Baker GJ, Kadiyala P, Erdreich-Epstein A, DeCarvalho AC et al (2016) CXCR4 increases in-vivo glioma perivascular invasion, and reduces radiation induced apoptosis: A genetic knockdown study. Oncotarget 7:83701\u201383719. https:\/\/doi.org\/10.18632\/oncotarget.13295","journal-title":"Oncotarget"},{"key":"5768_CR25","doi-asserted-by":"publisher","first-page":"4199","DOI":"10.3390\/ijms21124199","volume":"21","author":"M Novak","year":"2020","unstructured":"Novak M, Koprivnikar Krajnc M, Hrastar B, Breznik B, Majc B, Mlinar M et al (2020) CCR5-Mediated Signaling is Involved in Invasion of Glioblastoma Cells in Its Microenvironment. Int J Mol Sci 21:4199. https:\/\/doi.org\/10.3390\/ijms21124199","journal-title":"Int J Mol Sci"},{"key":"5768_CR26","doi-asserted-by":"publisher","first-page":"1534","DOI":"10.1038\/s43018-022-00475-x","volume":"3","author":"L Wang","year":"2022","unstructured":"Wang L, Jung J, Babikir H, Shamardani K, Jain S, Feng X et al (2022) A single-cell atlas of glioblastoma evolution under therapy reveals cell-intrinsic and cell-extrinsic therapeutic targets. Nat Cancer Nat Publishing Group 3:1534\u20131552. https:\/\/doi.org\/10.1038\/s43018-022-00475-x","journal-title":"Nat Cancer Nat Publishing Group"},{"key":"5768_CR27","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1172\/JCI40283","volume":"120","author":"M Kioi","year":"2010","unstructured":"Kioi M, Vogel H, Schultz G, Hoffman RM, Harsh GR, Brown JM (2010) Inhibition of vasculogenesis, but not angiogenesis, prevents the recurrence of glioblastoma after irradiation in mice. J Clin Invest Am Soc Clin Invest 120:694\u2013705. https:\/\/doi.org\/10.1172\/JCI40283","journal-title":"J Clin Invest Am Soc Clin Invest"},{"key":"5768_CR28","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1038\/s41419-019-1387-6","volume":"10","author":"T Hasan","year":"2019","unstructured":"Hasan T, Caragher SP, Shireman JM, Park CH, Atashi F, Baisiwala S et al (2019) Interleukin-8\/CXCR2 signaling regulates therapy-induced plasticity and enhances tumorigenicity in glioblastoma. Cell Death Dis 10:292. https:\/\/doi.org\/10.1038\/s41419-019-1387-6","journal-title":"Cell Death Dis"},{"key":"5768_CR29","doi-asserted-by":"publisher","first-page":"1072","DOI":"10.1038\/s41422-021-00528-3","volume":"31","author":"X-N Zhang","year":"2021","unstructured":"Zhang X-N, Yang K-D, Chen C, He Z-C, Wang Q-H, Feng H et al (2021) Pericytes augment glioblastoma cell resistance to temozolomide through CCL5-CCR5 paracrine signaling. Cell Res 31:1072\u20131087. https:\/\/doi.org\/10.1038\/s41422-021-00528-3","journal-title":"Cell Res"},{"key":"5768_CR30","doi-asserted-by":"publisher","first-page":"1264","DOI":"10.1038\/nm.3337","volume":"19","author":"SM Pyonteck","year":"2013","unstructured":"Pyonteck SM, Akkari L, Schuhmacher AJ, Bowman RL, Sevenich L, Quail DF et al (2013) CSF-1R inhibition alters macrophage polarization and blocks glioma progression. Nat Med 19:1264\u20131272. https:\/\/doi.org\/10.1038\/nm.3337","journal-title":"Nat Med"},{"key":"5768_CR31","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1016\/j.ccell.2021.05.002","volume":"39","author":"T Hara","year":"2021","unstructured":"Hara T, Chanoch-Myers R, Mathewson ND, Myskiw C, Atta L, Bussema L et al (2021) Interactions between cancer cells and immune cells drive transitions to mesenchymal-like states in glioblastoma. Cancer Cell 39:779\u2013792e11. https:\/\/doi.org\/10.1016\/j.ccell.2021.05.002","journal-title":"Cancer Cell"},{"key":"5768_CR32","doi-asserted-by":"publisher","first-page":"49481","DOI":"10.1074\/jbc.M206222200","volume":"277","author":"Y Zhou","year":"2002","unstructured":"Zhou Y, Larsen PH, Hao C, Yong VW (2002) CXCR4 is a major chemokine receptor on glioma cells and mediates their survival. J Biol Chem 277:49481\u201349487. https:\/\/doi.org\/10.1074\/jbc.M206222200","journal-title":"J Biol Chem"},{"key":"5768_CR33","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1016\/j.tox.2013.10.003","volume":"314","author":"M Gatti","year":"2013","unstructured":"Gatti M, Pattarozzi A, Bajetto A, W\u00fcrth R, Daga A, Fiaschi P et al (2013) Inhibition of CXCL12\/CXCR4 autocrine\/paracrine loop reduces viability of human glioblastoma stem-like cells affecting self-renewal activity. Toxicology 314:209\u2013220. https:\/\/doi.org\/10.1016\/j.tox.2013.10.003","journal-title":"Toxicology"},{"key":"5768_CR34","doi-asserted-by":"publisher","first-page":"2944","DOI":"10.1111\/febs.14466","volume":"285","author":"CE Hughes","year":"2018","unstructured":"Hughes CE, Nibbs RJB (2018) A guide to chemokines and their receptors. FEBS J 285:2944\u20132971. https:\/\/doi.org\/10.1111\/febs.14466","journal-title":"FEBS J"},{"key":"5768_CR35","doi-asserted-by":"publisher","unstructured":"Proudfoot AEI, Johnson Z, Bonvin P, Handel TM. Glycosaminoglycan interactions with chemokines add complexity to a complex system., Pharmaceuticals, Basel (2017) Basel, Switzerland. 10:70. https:\/\/doi.org\/10.3390\/ph10030070","DOI":"10.3390\/ph10030070"},{"key":"5768_CR36","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1038\/nri3544","volume":"13","author":"RJB Nibbs","year":"2013","unstructured":"Nibbs RJB, Graham GJ (2013) Immune regulation by atypical chemokine receptors. Nat Rev Immunol 13:815\u2013829. https:\/\/doi.org\/10.1038\/nri3544","journal-title":"Nat Rev Immunol"},{"key":"5768_CR37","doi-asserted-by":"publisher","first-page":"1045","DOI":"10.1172\/JCI114265","volume":"84","author":"M Baggiolini","year":"1989","unstructured":"Baggiolini M, Walz A, Kunkel SL (1989) Neutrophil-activating peptide-1\/interleukin 8, a novel cytokine that activates neutrophils. J Clin Invest 84:1045\u20131049. https:\/\/doi.org\/10.1172\/JCI114265","journal-title":"J Clin Invest"},{"key":"5768_CR38","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1038\/347669a0","volume":"347","author":"TJ Schall","year":"1990","unstructured":"Schall TJ, Bacon K, Toy KJ, Goeddel DV (1990) Selective attraction of monocytes and T lymphocytes of the memory phenotype by cytokine RANTES. Nature 347:669\u2013671. https:\/\/doi.org\/10.1038\/347669a0","journal-title":"Nature"},{"key":"5768_CR39","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1016\/j.cell.2019.06.024","volume":"178","author":"C Neftel","year":"2019","unstructured":"Neftel C, Laffy J, Filbin MG, Hara T, Shore ME, Rahme GJ et al (2019) An Integrative Model of Cellular States, Plasticity, and Genetics for Glioblastoma. Cell 178:835\u2013849e21. https:\/\/doi.org\/10.1016\/j.cell.2019.06.024","journal-title":"Cell"},{"key":"5768_CR40","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1016\/j.ccell.2022.05.009","volume":"40","author":"VM Ravi","year":"2022","unstructured":"Ravi VM, Will P, Kueckelhaus J, Sun N, Joseph K, Sali\u00e9 H et al (2022) Spatially resolved multi-omics deciphers bidirectional tumor-host interdependence in glioblastoma. Cancer Cell 40:639\u2013655e13. https:\/\/doi.org\/10.1016\/j.ccell.2022.05.009","journal-title":"Cancer Cell"},{"key":"5768_CR41","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","volume":"144","author":"D Hanahan","year":"2011","unstructured":"Hanahan D, Weinberg RA (2011) Hallmarks of Cancer: The Next Generation. Cell 144:646\u2013674. https:\/\/doi.org\/10.1016\/j.cell.2011.02.013","journal-title":"Cell"},{"key":"5768_CR42","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1158\/2159-8290.CD-21-1059","volume":"12","author":"D Hanahan","year":"2022","unstructured":"Hanahan D (2022) Hallmarks of Cancer: New Dimensions. Cancer Discov 12:31\u201346. https:\/\/doi.org\/10.1158\/2159-8290.CD-21-1059","journal-title":"Cancer Discov"},{"key":"5768_CR43","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1038\/313144a0","volume":"313","author":"TA Libermann","year":"1985","unstructured":"Libermann TA, Nusbaum HR, Razon N, Kris R, Lax I, Soreq H et al (1985) Amplification, enhanced expression and possible rearrangement of EGF receptor gene in primary human brain tumours of glial origin. Nat Nat Publishing Group 313:144\u2013147. https:\/\/doi.org\/10.1038\/313144a0","journal-title":"Nat Nat Publishing Group"},{"key":"5768_CR44","doi-asserted-by":"publisher","unstructured":"Ekstrand AJ, Sugawa N, James CD, Collins VP (1992) Amplified and rearranged epidermal growth factor receptor genes in human glioblastomas reveal deletions of sequences encoding portions of the N- and\/or C-terminal tails. Proceedings of the National Academy of Sciences. Proceedings of the National Academy of Sciences. 89:4309\u201313. https:\/\/doi.org\/10.1073\/pnas.89.10.4309","DOI":"10.1073\/pnas.89.10.4309"},{"key":"5768_CR45","doi-asserted-by":"publisher","first-page":"6846","DOI":"10.1158\/1078-0432.CCR-17-0890","volume":"23","author":"J Felsberg","year":"2017","unstructured":"Felsberg J, Hentschel B, Kaulich K, Gramatzki D, Zacher A, Malzkorn B et al (2017) Epidermal Growth Factor Receptor Variant III (EGFRvIII) Positivity in EGFR-Amplified Glioblastomas: Prognostic Role and Comparison between Primary and Recurrent Tumors. Clin Cancer Res 23:6846\u20136855. https:\/\/doi.org\/10.1158\/1078-0432.CCR-17-0890","journal-title":"Clin Cancer Res"},{"key":"5768_CR46","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1016\/j.ccr.2011.11.005","volume":"20","author":"M Snuderl","year":"2011","unstructured":"Snuderl M, Fazlollahi L, Le LP, Nitta M, Zhelyazkova BH, Davidson CJ et al (2011) Mosaic amplification of multiple receptor tyrosine kinase genes in glioblastoma. Cancer Cell 20:810\u2013817. https:\/\/doi.org\/10.1016\/j.ccr.2011.11.005","journal-title":"Cancer Cell"},{"key":"5768_CR47","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1126\/science.1241328","volume-title":"Targeted therapy resistance mediated by dynamic regulation of extrachromosomal mutant EGFR DNA","author":"DA Nathanson","year":"2014","unstructured":"Nathanson DA, Gini B, Mottahedeh J, Visnyei K, Koga T, Gomez G et al (2014) Targeted therapy resistance mediated by dynamic regulation of extrachromosomal mutant EGFR DNA, vol 343. Science, New York, N.Y., pp 72\u201376. https:\/\/doi.org\/10.1126\/science.1241328"},{"key":"5768_CR48","doi-asserted-by":"publisher","first-page":"1396","DOI":"10.1126\/science.1254257","volume-title":"Single-cell RNA-seq highlights intratumoral heterogeneity in primary glioblastoma","author":"AP Patel","year":"2014","unstructured":"Patel AP, Tirosh I, Trombetta JJ, Shalek AK, Gillespie SM, Wakimoto H et al (2014) Single-cell RNA-seq highlights intratumoral heterogeneity in primary glioblastoma, vol 344. Science, New York, N, pp 1396\u20131401. https:\/\/doi.org\/10.1126\/science.1254257"},{"key":"5768_CR49","doi-asserted-by":"publisher","first-page":"956","DOI":"10.1158\/2159-8290.CD-13-0879","volume":"4","author":"JM Francis","year":"2014","unstructured":"Francis JM, Zhang C-Z, Maire CL, Jung J, Manzo VE, Adalsteinsson VA et al (2014) EGFR Variant Heterogeneity in Glioblastoma Resolved through Single-Nucleus Sequencing. Cancer Discov 4:956\u2013971. https:\/\/doi.org\/10.1158\/2159-8290.CD-13-0879","journal-title":"Cancer Discov"},{"key":"5768_CR50","doi-asserted-by":"publisher","first-page":"935","DOI":"10.1093\/neuonc\/nov013","volume":"17","author":"MJ van den Bent","year":"2015","unstructured":"van den Bent MJ, Gao Y, Kerkhof M, Kros JM, Gorlia T, van Zwieten K et al (2015) Changes in the EGFR amplification and EGFRvIII expression between paired primary and recurrent glioblastomas. Neuro Oncol 17:935\u2013941. https:\/\/doi.org\/10.1093\/neuonc\/nov013","journal-title":"Neuro Oncol"},{"key":"5768_CR51","first-page":"1969","volume":"63","author":"S Barbero","year":"2003","unstructured":"Barbero S, Bonavia R, Bajetto A, Porcile C, Pirani P, Ravetti JL et al (2003) Stromal cell-derived factor 1alpha stimulates human glioblastoma cell growth through the activation of both extracellular signal-regulated kinases 1\/2 and Akt. Cancer Res 63:1969\u20131974","journal-title":"Cancer Res"},{"key":"5768_CR52","doi-asserted-by":"publisher","first-page":"1250","DOI":"10.1158\/1078-0432.CCR-15-2888","volume":"23","author":"A-A Calinescu","year":"2017","unstructured":"Calinescu A-A, Yadav VN, Carballo E, Kadiyala P, Tran D, Zamler DB et al (2017) Survival and Proliferation of Neural Progenitor\u2013Derived Glioblastomas Under Hypoxic Stress is Controlled by a CXCL12\/CXCR4 Autocrine-Positive Feedback Mechanism. Clin Cancer Res 23:1250\u20131262. https:\/\/doi.org\/10.1158\/1078-0432.CCR-15-2888","journal-title":"Clin Cancer Res"},{"key":"5768_CR53","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1101\/gad.1606508","volume":"22","author":"N de la Iglesia","year":"2008","unstructured":"de la Iglesia N, Konopka G, Puram SV, Chan JA, Bachoo RM, You MJ et al (2008) Identification of a PTEN-regulated STAT3 brain tumor suppressor pathway. Genes Dev 22:449\u2013462. https:\/\/doi.org\/10.1101\/gad.1606508","journal-title":"Genes Dev"},{"key":"5768_CR54","doi-asserted-by":"publisher","first-page":"5870","DOI":"10.1523\/JNEUROSCI.5385-07.2008","volume":"28","author":"N de la Iglesia","year":"2008","unstructured":"de la Iglesia N, Konopka G, Lim K-L, Nutt CL, Bromberg JF, Frank DA et al (2008) Deregulation of a STAT3\u2013Interleukin 8 Signaling Pathway Promotes Human Glioblastoma Cell Proliferation and Invasiveness. J Neurosci 28:5870\u20135878. https:\/\/doi.org\/10.1523\/JNEUROSCI.5385-07.2008","journal-title":"J Neurosci"},{"key":"5768_CR55","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1016\/j.canlet.2008.09.034","volume":"274","author":"M Ehtesham","year":"2009","unstructured":"Ehtesham M, Mapara KY, Stevenson CB, Thompson RC (2009) CXCR4 mediates the proliferation of glioblastoma progenitor cells. Cancer Lett 274:305\u2013312. https:\/\/doi.org\/10.1016\/j.canlet.2008.09.034","journal-title":"Cancer Lett"},{"key":"5768_CR56","first-page":"102","volume":"6","author":"SA Rempel","year":"2000","unstructured":"Rempel SA, Dudas S, Ge S, Guti\u00e9rrez JA (2000) Identification and localization of the cytokine SDF1 and its receptor, CXC chemokine receptor 4, to regions of necrosis and angiogenesis in human glioblastoma. Clin Cancer Res 6:102\u2013111","journal-title":"Clin Cancer Res"},{"key":"5768_CR57","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1016\/j.neuint.2006.03.003","volume":"49","author":"A Bajetto","year":"2006","unstructured":"Bajetto A, Barbieri F, Dorcaratto A, Barbero S, Daga A, Porcile C et al (2006) Expression of CXC chemokine receptors 1\u20135 and their ligands in human glioma tissues: Role of CXCR4 and SDF1 in glioma cell proliferation and migration. Neurochem Int 49:423\u2013432. https:\/\/doi.org\/10.1016\/j.neuint.2006.03.003","journal-title":"Neurochem Int"},{"key":"5768_CR58","doi-asserted-by":"publisher","first-page":"2801","DOI":"10.1038\/sj.onc.1209302","volume":"25","author":"M Ehtesham","year":"2006","unstructured":"Ehtesham M, Winston JA, Kabos P, Thompson RC (2006) CXCR4 expression mediates glioma cell invasiveness. Oncogene 25:2801\u20132806. https:\/\/doi.org\/10.1038\/sj.onc.1209302","journal-title":"Oncogene"},{"key":"5768_CR59","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1093\/neuonc\/nou144","volume":"17","author":"N Goffart","year":"2015","unstructured":"Goffart N, Kroonen J, Di Valentin E, Dedobbeleer M, Denne A, Martinive P et al (2015) Adult mouse subventricular zones stimulate glioblastoma stem cells specific invasion through CXCL12\/CXCR4 signaling. Neuro Oncol 17:81\u201394. https:\/\/doi.org\/10.1093\/neuonc\/nou144","journal-title":"Neuro Oncol"},{"key":"5768_CR60","doi-asserted-by":"publisher","first-page":"545","DOI":"10.2353\/ajpath.2008.071197","volume":"173","author":"D Zagzag","year":"2008","unstructured":"Zagzag D, Esencay M, Mendez O, Yee H, Smirnova I, Huang Y et al (2008) Hypoxia- and vascular endothelial growth factor-induced stromal cell-derived factor-1alpha\/CXCR4 expression in glioblastomas: one plausible explanation of Scherer\u2019s structures. Am J Pathol 173:545\u2013560. https:\/\/doi.org\/10.2353\/ajpath.2008.071197","journal-title":"Am J Pathol"},{"key":"5768_CR61","doi-asserted-by":"publisher","first-page":"13513","DOI":"10.1073\/pnas.2235846100","volume":"100","author":"JB Rubin","year":"2003","unstructured":"Rubin JB, Kung AL, Klein RS, Chan JA, Sun Y, Schmidt K et al (2003) A small-molecule antagonist of CXCR4 inhibits intracranial growth of primary brain tumors. Proc Natl Acad Sci U S A 100:13513\u201313518. https:\/\/doi.org\/10.1073\/pnas.2235846100","journal-title":"Proc Natl Acad Sci U S A"},{"key":"5768_CR62","doi-asserted-by":"publisher","first-page":"56","DOI":"10.4161\/cbt.9.1.10342","volume":"9","author":"A do Carmo","year":"2010","unstructured":"do Carmo A, Patricio I, Cruz MT, Carvalheiro H, Oliveira CR, Lopes MC (2010) CXCL12\/CXCR4 promotes motility and proliferation of glioma cells. Cancer Biol Ther 9:56\u201365. https:\/\/doi.org\/10.4161\/cbt.9.1.10342","journal-title":"Cancer Biol Ther"},{"key":"5768_CR63","doi-asserted-by":"publisher","first-page":"4643","DOI":"10.1158\/1078-0432.CCR-18-1025","volume":"24","author":"EQ Lee","year":"2018","unstructured":"Lee EQ, Duda DG, Muzikansky A, Gerstner ER, Kuhn JG, Reardon DA et al (2018) Phase I and Biomarker Study of Plerixafor and Bevacizumab in Recurrent High-Grade Glioma. Clin Cancer Res 24:4643\u20134649. https:\/\/doi.org\/10.1158\/1078-0432.CCR-18-1025","journal-title":"Clin Cancer Res"},{"key":"5768_CR64","doi-asserted-by":"publisher","first-page":"4904","DOI":"10.1038\/s41467-018-07334-3","volume":"9","author":"EC Randall","year":"2018","unstructured":"Randall EC, Emdal KB, Laramy JK, Kim M, Roos A, Calligaris D et al (2018) Integrated mapping of pharmacokinetics and pharmacodynamics in a patient-derived xenograft model of glioblastoma. Nat Commun Nat Publishing Group 9:4904. https:\/\/doi.org\/10.1038\/s41467-018-07334-3","journal-title":"Nat Commun Nat Publishing Group"},{"key":"5768_CR65","doi-asserted-by":"publisher","first-page":"1595","DOI":"10.1158\/1078-0432.CCR-21-1933","volume":"28","author":"ME van Linde","year":"2022","unstructured":"van Linde ME, Labots M, Brahm CG, Hovinga KE, De Witt Hamer PC, Honeywell RJ et al (2022) Tumor Drug Concentration and Phosphoproteomic Profiles After Two Weeks of Treatment With Sunitinib in Patients with Newly Diagnosed Glioblastoma. Clin Cancer Res 28:1595\u20131602. https:\/\/doi.org\/10.1158\/1078-0432.CCR-21-1933","journal-title":"Clin Cancer Res"},{"key":"5768_CR66","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1200\/JCO.18.01207","volume":"37","author":"PY Wen","year":"2019","unstructured":"Wen PY, Touat M, Alexander BM, Mellinghoff IK, Ramkissoon S, McCluskey CS et al (2019) Buparlisib in Patients With Recurrent Glioblastoma Harboring Phosphatidylinositol 3-Kinase Pathway Activation: An Open-Label, Multicenter, Multi-Arm, Phase II Trial. J Clin Oncol 37:741\u2013750. https:\/\/doi.org\/10.1200\/JCO.18.01207","journal-title":"J Clin Oncol"},{"key":"5768_CR67","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1093\/neuonc\/now136","volume":"19","author":"N Goffart","year":"2017","unstructured":"Goffart N, Lombard A, Lallemand F, Kroonen J, Nassen J, Di Valentin E et al (2017) CXCL12 mediates glioblastoma resistance to radiotherapy in the subventricular zone. Neuro Oncol 19:66\u201377. https:\/\/doi.org\/10.1093\/neuonc\/now136","journal-title":"Neuro Oncol"},{"key":"5768_CR68","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1016\/j.ccell.2018.08.003","volume":"34","author":"A Mancini","year":"2018","unstructured":"Mancini A, Xavier-Magalh\u00e3es A, Woods WS, Nguyen K-T, Amen AM, Hayes JL et al (2018) Disruption of the \u03b21L Isoform of GABP Reverses Glioblastoma Replicative Immortality in a TERT Promoter Mutation-Dependent Manner. Cancer Cell 34:513\u2013528e8. https:\/\/doi.org\/10.1016\/j.ccell.2018.08.003","journal-title":"Cancer Cell"},{"key":"5768_CR69","doi-asserted-by":"publisher","first-page":"1036","DOI":"10.1126\/science.aab0015","volume":"348","author":"RJA Bell","year":"2015","unstructured":"Bell RJA, Rube HT, Kreig A, Mancini A, Fouse SD, Nagarajan RP et al (2015) The transcription factor GABP selectively binds and activates the mutant TERT promoter in cancer. Sci Am Association Advancement Sci 348:1036\u20131039. https:\/\/doi.org\/10.1126\/science.aab0015","journal-title":"Sci Am Association Advancement Sci"},{"key":"5768_CR70","doi-asserted-by":"publisher","first-page":"e07918","DOI":"10.7554\/eLife.07918","volume":"4","author":"K Chiba","year":"2015","unstructured":"Chiba K, Johnson JZ, Vogan JM, Wagner T, Boyle JM, Hockemeyer D (2015) Cancer-associated TERT promoter mutations abrogate telomerase silencing. Elife 4:e07918. https:\/\/doi.org\/10.7554\/eLife.07918","journal-title":"Elife"},{"key":"5768_CR71","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1016\/j.neuron.2025.12.012","volume":"114","author":"N Mikolajewicz","year":"2026","unstructured":"Mikolajewicz N, Zhai K, Puri A, Miletic P, Tatari N, Wei J et al (2026) Reactive oligodendrocytes promote glioblastoma progression through CCL5\/CCR5-mediated glioma stem cell maintenance. Neuron 114:237\u2013249e10. https:\/\/doi.org\/10.1016\/j.neuron.2025.12.012","journal-title":"Neuron"},{"key":"5768_CR72","doi-asserted-by":"publisher","first-page":"1327","DOI":"10.1038\/ncb3240","volume":"17","author":"Y Li","year":"2015","unstructured":"Li Y, Zhou Q-L, Sun W, Chandrasekharan P, Cheng HS, Ying Z et al (2015) Non-canonical NF-\u03baB signalling and ETS1\/2 cooperatively drive C250T mutant TERT promoter activation. Nat Cell Biol 17:1327\u20131338. https:\/\/doi.org\/10.1038\/ncb3240","journal-title":"Nat Cell Biol"},{"key":"5768_CR73","doi-asserted-by":"publisher","first-page":"3708","DOI":"10.1038\/sj.onc.1207460","volume":"23","author":"N Yatabe","year":"2004","unstructured":"Yatabe N, Kyo S, Maida Y, Nishi H, Nakamura M, Kanaya T et al (2004) HIF-1-mediated activation of telomerase in cervical cancer cells. Oncogene 23:3708\u20133715. https:\/\/doi.org\/10.1038\/sj.onc.1207460","journal-title":"Oncogene"},{"key":"5768_CR74","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1158\/1541-7786.MCR-07-0065","volume":"5","author":"F Lou","year":"2007","unstructured":"Lou F, Chen X, Jalink M, Zhu Q, Ge N, Zhao S et al (2007) The opposing effect of hypoxia-inducible factor-2alpha on expression of telomerase reverse transcriptase. Mol Cancer Res 5:793\u2013800. https:\/\/doi.org\/10.1158\/1541-7786.MCR-07-0065","journal-title":"Mol Cancer Res"},{"key":"5768_CR75","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1016\/S1470-2045(09)70025-7","volume":"10","author":"R Stupp","year":"2009","unstructured":"Stupp R, Hegi ME, Mason WP, van den Bent MJ, Taphoorn MJB, Janzer RC et al (2009) Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol 10:459\u2013466. https:\/\/doi.org\/10.1016\/S1470-2045(09)70025-7","journal-title":"Lancet Oncol"},{"key":"5768_CR76","doi-asserted-by":"publisher","first-page":"678","DOI":"10.1016\/S0140-6736(18)31791-4","volume":"393","author":"U Herrlinger","year":"2019","unstructured":"Herrlinger U, Tzaridis T, Mack F, Steinbach JP, Schlegel U, Sabel M et al (2019) Lomustine-temozolomide combination therapy versus standard temozolomide therapy in patients with newly diagnosed glioblastoma with methylated MGMT promoter (CeTeG\/NOA\u201309): a randomised, open-label, phase 3 trial. Lancet Elsevier 393:678\u2013688. https:\/\/doi.org\/10.1016\/S0140-6736(18)31791-4","journal-title":"Lancet Elsevier"},{"key":"5768_CR77","doi-asserted-by":"publisher","first-page":"2306","DOI":"10.1001\/jama.2017.18718","volume":"318","author":"R Stupp","year":"2017","unstructured":"Stupp R, Taillibert S, Kanner A, Read W, Steinberg DM, Lhermitte B et al (2017) Effect of Tumor-Treating Fields Plus Maintenance Temozolomide vs Maintenance Temozolomide Alone on Survival in Patients With Glioblastoma: A Randomized Clinical Trial. JAMA 318:2306\u20132316. https:\/\/doi.org\/10.1001\/jama.2017.18718","journal-title":"JAMA"},{"key":"5768_CR78","doi-asserted-by":"publisher","first-page":"6948","DOI":"10.1158\/1078-0432.CCR-19-1421","volume":"25","author":"RP Thomas","year":"2019","unstructured":"Thomas RP, Nagpal S, Iv M, Soltys SG, Bertrand S, Pelpola JS et al (2019) Macrophage Exclusion after Radiation Therapy (MERT): A First in Human Phase I\/II Trial using a CXCR4 Inhibitor in Glioblastoma. Clin Cancer Res 25:6948\u20136957. https:\/\/doi.org\/10.1158\/1078-0432.CCR-19-1421","journal-title":"Clin Cancer Res"},{"key":"5768_CR79","doi-asserted-by":"publisher","first-page":"890","DOI":"10.1097\/QAD.0b013e328351f627","volume":"26","author":"D CROTEAU","year":"2012","unstructured":"CROTEAU D, BEST BM, LETENDRE S, ROSSI SS, ELLIS RJ, CLIFFORD DB et al (2012) Lower Than Expected Maraviroc Concentrations in Cerebrospinal Fluid Exceed the Wild-Type CCR5-tropic HIV-1 50% Inhibitory Concentration. AIDS 26:890\u2013893. https:\/\/doi.org\/10.1097\/QAD.0b013e328351f627","journal-title":"AIDS"},{"key":"5768_CR80","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1126\/science.1239947","volume-title":"Mutational analysis reveals the origin and therapy-driven evolution of recurrent glioma","author":"BE Johnson","year":"2014","unstructured":"Johnson BE, Mazor T, Hong C, Barnes M, Aihara K, McLean CY et al (2014) Mutational analysis reveals the origin and therapy-driven evolution of recurrent glioma, vol 343. Science, New York, N.Y., pp 189\u2013193. https:\/\/doi.org\/10.1126\/science.1239947"},{"key":"5768_CR81","doi-asserted-by":"publisher","first-page":"768","DOI":"10.1038\/ng.3590","volume":"48","author":"J Wang","year":"2016","unstructured":"Wang J, Cazzato E, Ladewig E, Frattini V, Rosenbloom DIS, Zairis S et al (2016) Clonal evolution of glioblastoma under therapy. Nat Genet Nat Publishing Group 48:768\u2013776. https:\/\/doi.org\/10.1038\/ng.3590","journal-title":"Nat Genet Nat Publishing Group"},{"key":"5768_CR82","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1038\/s41586-019-1775-1","volume":"576","author":"FP Barthel","year":"2019","unstructured":"Barthel FP, Johnson KC, Varn FS, Moskalik AD, Tanner G, Kocakavuk E et al (2019) Longitudinal molecular trajectories of diffuse glioma in adults. Nat Nat Publishing Group 576:112\u2013120. https:\/\/doi.org\/10.1038\/s41586-019-1775-1","journal-title":"Nat Nat Publishing Group"},{"key":"5768_CR83","doi-asserted-by":"publisher","first-page":"3987","DOI":"10.1158\/0008-5472.CAN-06-0127","volume":"66","author":"C Hunter","year":"2006","unstructured":"Hunter C, Smith R, Cahill DP, Stephens P, Stevens C, Teague J et al (2006) A hypermutation phenotype and somatic MSH6 mutations in recurrent human malignant gliomas after alkylator chemotherapy. Cancer Res 66:3987\u20133991. https:\/\/doi.org\/10.1158\/0008-5472.CAN-06-0127","journal-title":"Cancer Res"},{"key":"5768_CR84","doi-asserted-by":"publisher","first-page":"144","DOI":"10.3389\/fncel.2014.00144","volume":"8","author":"R W\u00fcrth","year":"2014","unstructured":"W\u00fcrth R, Bajetto A, Harrison JK, Barbieri F, Florio T (2014) CXCL12 modulation of CXCR4 and CXCR7 activity in human glioblastoma stem-like cells and regulation of the tumor microenvironment. Front Cell Neurosci 8:144. https:\/\/doi.org\/10.3389\/fncel.2014.00144","journal-title":"Front Cell Neurosci"},{"key":"5768_CR85","doi-asserted-by":"publisher","first-page":"21925","DOI":"10.1038\/s41598-024-73064-w","volume":"14","author":"D Isci","year":"2024","unstructured":"Isci D, Kuppens A, Scalisi J, Cokaiko J, D\u2019Uonnolo G, Wantz M et al (2024) Heterogeneous expression of the atypical chemokine receptor ACKR3 in glioblastoma patient-derived tissue samples and cell cultures. Sci Rep 14:21925. https:\/\/doi.org\/10.1038\/s41598-024-73064-w","journal-title":"Sci Rep"},{"key":"5768_CR86","doi-asserted-by":"publisher","first-page":"116837","DOI":"10.1016\/j.jns.2020.116837","volume":"414","author":"S Wang","year":"2020","unstructured":"Wang S, Chen C, Li J, Xu X, Chen W, Li F (2020) The CXCL12\/CXCR4 axis confers temozolomide resistance to human glioblastoma cells via up-regulation of FOXM1. J Neurol Sci 414:116837. https:\/\/doi.org\/10.1016\/j.jns.2020.116837","journal-title":"J Neurol Sci"},{"key":"5768_CR87","doi-asserted-by":"publisher","first-page":"11664","DOI":"10.18632\/oncotarget.3256","volume":"6","author":"E Tabouret","year":"2015","unstructured":"Tabouret E, Tchoghandjian A, Denicolai E, Delfino C, Metellus P, Graillon T et al (2015) Recurrence of glioblastoma after radio-chemotherapy is associated with an angiogenic switch to the CXCL12-CXCR4 pathway. Oncotarget 6:11664\u201311675. https:\/\/doi.org\/10.18632\/oncotarget.3256","journal-title":"Oncotarget"},{"key":"5768_CR88","doi-asserted-by":"publisher","first-page":"1199","DOI":"10.1158\/2326-6066.CIR-14-0099","volume":"2","author":"T Ohkuri","year":"2014","unstructured":"Ohkuri T, Ghosh A, Kosaka A, Zhu J, Ikeura M, David M et al (2014) STING contributes to antiglioma immunity via triggering type I IFN signals in the tumor microenvironment. Cancer Immunol Res 2:1199\u20131208. https:\/\/doi.org\/10.1158\/2326-6066.CIR-14-0099","journal-title":"Cancer Immunol Res"},{"key":"5768_CR89","doi-asserted-by":"publisher","first-page":"e111961","DOI":"10.15252\/embj.2022111961","volume":"42","author":"C Taffoni","year":"2023","unstructured":"Taffoni C, Marines J, Chamma H, Guha S, Saccas M, Bouzid A et al (2023) DNA damage repair kinase DNA-PK and cGAS synergize to induce cancer-related inflammation in glioblastoma. EMBO J 42:e111961. https:\/\/doi.org\/10.15252\/embj.2022111961","journal-title":"EMBO J"},{"key":"5768_CR90","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1093\/neuonc\/not149","volume":"16","author":"S-C Liu","year":"2014","unstructured":"Liu S-C, Alomran R, Chernikova SB, Lartey F, Stafford J, Jang T et al (2014) Blockade of SDF-1 after irradiation inhibits tumor recurrences of autochthonous brain tumors in rats. Neuro Oncol 16:21\u201328. https:\/\/doi.org\/10.1093\/neuonc\/not149","journal-title":"Neuro Oncol"},{"key":"5768_CR91","doi-asserted-by":"publisher","first-page":"1179","DOI":"10.1038\/bjc.2013.830","volume":"110","author":"MJ Walters","year":"2014","unstructured":"Walters MJ, Ebsworth K, Berahovich RD, Penfold MET, Liu S-C, Al Omran R et al (2014) Inhibition of CXCR7 extends survival following irradiation of brain tumours in mice and rats. Br J Cancer Nat Publishing Group 110:1179\u20131188. https:\/\/doi.org\/10.1038\/bjc.2013.830","journal-title":"Br J Cancer Nat Publishing Group"},{"key":"5768_CR92","doi-asserted-by":"publisher","unstructured":"Berger G, Knelson EH, Jimenez-Macias JL, Nowicki MO, Han S, Panagioti E et al (2022) STING activation promotes robust immune response and NK cell\u2013mediated tumor regression in glioblastoma models. Proceedings of the National Academy of Sciences. Proceedings of the National Academy of Sciences. 119:e2111003119. https:\/\/doi.org\/10.1073\/pnas.2111003119","DOI":"10.1073\/pnas.2111003119"},{"key":"5768_CR93","doi-asserted-by":"publisher","first-page":"e175033","DOI":"10.1172\/JCI175033","volume":"134","author":"H Najem","year":"2024","unstructured":"Najem H, Lea ST, Tripathi S, Hurley L, Chen C-H, William I et al (2024) STING agonist 8803 reprograms the immune microenvironment and increases survival in preclinical models of glioblastoma. J Clin Invest 134:e175033. https:\/\/doi.org\/10.1172\/JCI175033","journal-title":"J Clin Invest"},{"key":"5768_CR94","doi-asserted-by":"publisher","first-page":"1610","DOI":"10.1038\/s41467-023-37328-9","volume":"14","author":"P Zhang","year":"2023","unstructured":"Zhang P, Rashidi A, Zhao J, Silvers C, Wang H, Castro B et al (2023) STING agonist-loaded, CD47\/PD-L1-targeting nanoparticles potentiate antitumor immunity and radiotherapy for glioblastoma. Nat Commun Nat Publishing Group 14:1610. https:\/\/doi.org\/10.1038\/s41467-023-37328-9","journal-title":"Nat Commun Nat Publishing Group"},{"key":"5768_CR95","doi-asserted-by":"publisher","first-page":"216480","DOI":"10.1016\/j.canlet.2023.216480","volume":"579","author":"JV Joseph","year":"2023","unstructured":"Joseph JV, Blaavand MS, Cai H, Vernejoul F, Knopper RW, Lindhardt TB et al (2023) STING activation counters glioblastoma by vascular alteration and immune surveillance. Cancer Lett 579:216480. https:\/\/doi.org\/10.1016\/j.canlet.2023.216480","journal-title":"Cancer Lett"},{"key":"5768_CR96","doi-asserted-by":"publisher","first-page":"v152","DOI":"10.1093\/neuonc\/noaf201.0599","volume":"27","author":"N Majd","year":"2025","unstructured":"Majd N, Dagher S-A, Wang S, Salvatierra M, Soto LS, Liu SJ et al (2025) DNAR-08. Phase I Trial of Peposertib (DNA-PK inhibitor) Plus Radiation in Newly Diagnosed MGMT-Unmethylated Glioblastoma, Updated Clinical, Radiographic, and Biomarker Outcomes. Neuro Oncol 27:v152. https:\/\/doi.org\/10.1093\/neuonc\/noaf201.0599","journal-title":"Neuro Oncol"},{"key":"5768_CR97","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1038\/s41419-025-08226-3","volume":"17","author":"MR Saathoff","year":"2025","unstructured":"Saathoff MR, Chojak R, Chen RX, Kazi HA, Faisal UH, Shireman JM et al (2025) LMNA-PRKDC axis enhances DNA repair and promotes chemoresistance in glioblastoma. Cell Death Dis Nat Publishing Group 17:50. https:\/\/doi.org\/10.1038\/s41419-025-08226-3","journal-title":"Cell Death Dis Nat Publishing Group"},{"key":"5768_CR98","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1038\/359845a0","volume":"359","author":"KH Plate","year":"1992","unstructured":"Plate KH, Breier G, Weich HA, Risau W (1992) Vascular endothelial growth factor is a potential tumour angiogenesis factor in human gliomas in vivo. Nat Nat Publishing Group 359:845\u2013848. https:\/\/doi.org\/10.1038\/359845a0","journal-title":"Nat Nat Publishing Group"},{"key":"5768_CR99","doi-asserted-by":"publisher","first-page":"4733","DOI":"10.1200\/JCO.2008.19.8721","volume":"27","author":"HS Friedman","year":"2009","unstructured":"Friedman HS, Prados MD, Wen PY, Mikkelsen T, Schiff D, Abrey LE et al (2009) Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J Clin Oncol 27:4733\u20134740. https:\/\/doi.org\/10.1200\/JCO.2008.19.8721","journal-title":"J Clin Oncol"},{"key":"5768_CR100","doi-asserted-by":"publisher","first-page":"1329","DOI":"10.1634\/theoncologist.2010-0105","volume":"15","author":"JJ Vredenburgh","year":"2010","unstructured":"Vredenburgh JJ, Cloughesy T, Samant M, Prados M, Wen PY, Mikkelsen T et al (2010) Corticosteroid use in patients with glioblastoma at first or second relapse treated with bevacizumab in the BRAIN study. Oncologist 15:1329\u20131334. https:\/\/doi.org\/10.1634\/theoncologist.2010-0105","journal-title":"Oncologist"},{"key":"5768_CR101","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1158\/1078-0432.CCR-19-1739","volume":"26","author":"ER Gerstner","year":"2020","unstructured":"Gerstner ER, Emblem KE, Chang K, Vakulenko-Lagun B, Yen Y-F, Beers AL et al (2020) Bevacizumab Reduces Permeability and Concurrent Temozolomide Delivery in a Subset of Patients with Recurrent Glioblastoma. Clin Cancer Res 26:206\u2013212. https:\/\/doi.org\/10.1158\/1078-0432.CCR-19-1739","journal-title":"Clin Cancer Res"},{"key":"5768_CR102","doi-asserted-by":"publisher","first-page":"1201","DOI":"10.1084\/jem.186.8.1201","volume":"186","author":"I Desbaillets","year":"1997","unstructured":"Desbaillets I, Diserens AC, Tribolet N, Hamou MF, Van Meir EG (1997) Upregulation of interleukin 8 by oxygen-deprived cells in glioblastoma suggests a role in leukocyte activation, chemotaxis, and angiogenesis. J Exp Med 186:1201\u20131212. https:\/\/doi.org\/10.1084\/jem.186.8.1201","journal-title":"J Exp Med"},{"key":"5768_CR103","doi-asserted-by":"publisher","first-page":"27348","DOI":"10.1074\/jbc.270.45.27348","volume":"270","author":"RM Strieter","year":"1995","unstructured":"Strieter RM, Polverini PJ, Kunkel SL, Arenberg DA, Burdick MD, Kasper J et al (1995) The Functional Role of the ELR Motif in CXC Chemokine-mediated Angiogenesis (*). J Biol Chem 270:27348\u201327357. https:\/\/doi.org\/10.1074\/jbc.270.45.27348","journal-title":"J Biol Chem"},{"key":"5768_CR104","doi-asserted-by":"publisher","unstructured":"Addison CL, Daniel TO, Burdick MD, Liu H, Ehlert JE, Xue YY et al (1950) The CXC chemokine receptor 2, CXCR2, is the putative receptor for ELR\u2009+\u2009CXC chemokine-induced angiogenic activity. J Immunol. Baltimore, Md. 2000;165:5269\u201377. https:\/\/doi.org\/10.4049\/jimmunol.165.9.5269","DOI":"10.4049\/jimmunol.165.9.5269"},{"key":"5768_CR105","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/j.canlet.2015.02.005","volume":"360","author":"K Pham","year":"2015","unstructured":"Pham K, Luo D, Siemann DW, Law BK, Reynolds BA, Hothi P et al (2015) VEGFR inhibitors upregulate CXCR4 in VEGF receptor-expressing glioblastoma in a TGF\u03b2R signaling-dependent manner. Cancer Lett 360:60\u201367. https:\/\/doi.org\/10.1016\/j.canlet.2015.02.005","journal-title":"Cancer Lett"},{"key":"5768_CR106","doi-asserted-by":"publisher","first-page":"1798","DOI":"10.1126\/science.1281554","volume-title":"Interleukin-8 as a macrophage-derived mediator of angiogenesis","author":"AE Koch","year":"1992","unstructured":"Koch AE, Polverini PJ, Kunkel SL, Harlow LA, DiPietro LA, Elner VM et al (1992) Interleukin-8 as a macrophage-derived mediator of angiogenesis, vol 258. Science, New York, N, pp 1798\u20131801. https:\/\/doi.org\/10.1126\/science.1281554"},{"key":"5768_CR107","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1016\/j.ejca.2019.12.005","volume":"126","author":"G Acker","year":"2020","unstructured":"Acker G, Zollfrank J, Jelgersma C, Nieminen-Kelh\u00e4 M, Kremenetskaia I, Mueller S et al (2020) The CXCR2\/CXCL2 signalling pathway - An alternative therapeutic approach in high-grade glioma. Eur J Cancer 126:106\u2013115. https:\/\/doi.org\/10.1016\/j.ejca.2019.12.005","journal-title":"Eur J Cancer"},{"key":"5768_CR108","doi-asserted-by":"publisher","first-page":"4210","DOI":"10.1038\/s41467-024-48416-9","volume":"15","author":"FA Giordano","year":"2024","unstructured":"Giordano FA, Layer JP, Leonardelli S, Friker LL, Turiello R, Corvino D et al (2024) L-RNA aptamer-based CXCL12 inhibition combined with radiotherapy in newly-diagnosed glioblastoma: dose escalation of the phase I\/II GLORIA trial. Nat Commun Nat Publishing Group 15:4210. https:\/\/doi.org\/10.1038\/s41467-024-48416-9","journal-title":"Nat Commun Nat Publishing Group"},{"key":"5768_CR109","doi-asserted-by":"publisher","first-page":"3405","DOI":"10.1038\/s41467-026-71362-7","volume":"17","author":"FA Giordano","year":"2026","unstructured":"Giordano FA, Layer JP, Turiello R, Friker LL, Mirallas O, Pregler BEF et al (2026) L-RNA aptamer-based CXCL12 inhibition combined with radiotherapy and bevacizumab in newly-diagnosed glioblastoma: expansion of the phase I\/II GLORIA trial. Nat Commun Nat Publishing Group 17:3405. https:\/\/doi.org\/10.1038\/s41467-026-71362-7","journal-title":"Nat Commun Nat Publishing Group"},{"key":"5768_CR110","doi-asserted-by":"publisher","first-page":"11085","DOI":"10.1038\/s41598-019-47438-4","volume":"9","author":"HR Cho","year":"2019","unstructured":"Cho HR, Kumari N, Thi Vu H, Kim H, Park C-K, Choi SH (2019) Increased Antiangiogenic Effect by Blocking CCL2-dependent Macrophages in a Rodent Glioblastoma Model: Correlation Study with Dynamic Susceptibility Contrast Perfusion MRI. Sci Rep Nat Publishing Group 9:11085. https:\/\/doi.org\/10.1038\/s41598-019-47438-4","journal-title":"Sci Rep Nat Publishing Group"},{"key":"5768_CR111","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1074\/jbc.M116.762252","volume":"292","author":"B Benredjem","year":"2017","unstructured":"Benredjem B, Girard M, Rhainds D, St.-Onge G, Heveker N (2017) Mutational Analysis of Atypical Chemokine Receptor 3 (ACKR3\/CXCR7) Interaction with Its Chemokine Ligands CXCL11 and CXCL12. J Biol Chem 292:31\u201342. https:\/\/doi.org\/10.1074\/jbc.M116.762252","journal-title":"J Biol Chem"},{"key":"5768_CR112","doi-asserted-by":"publisher","first-page":"1354","DOI":"10.1016\/j.ymthe.2018.02.030","volume":"26","author":"N Salazar","year":"2018","unstructured":"Salazar N, Carlson JC, Huang K, Zheng Y, Oderup C, Gross J et al (2018) A Chimeric Antibody against ACKR3\/CXCR7 in Combination with TMZ Activates Immune Responses and Extends Survival in Mouse GBM Models. Mol Ther 26:1354\u20131365. https:\/\/doi.org\/10.1016\/j.ymthe.2018.02.030","journal-title":"Mol Ther"},{"key":"5768_CR113","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1002\/path.5569","volume":"253","author":"A Blank","year":"2021","unstructured":"Blank A, Kremenetskaia I, Urbantat RM, Acker G, Turkowski K, Radke J et al (2021) Microglia\/macrophages express alternative proangiogenic factors depending on granulocyte content in human glioblastoma. J Pathol 253:160\u2013173. https:\/\/doi.org\/10.1002\/path.5569","journal-title":"J Pathol"},{"key":"5768_CR114","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1007\/s11060-011-0575-8","volume":"105","author":"M Lun","year":"2011","unstructured":"Lun M, Lok E, Gautam S, Wu E, Wong ET (2011) The natural history of extracranial metastasis from glioblastoma multiforme. J Neurooncol 105:261\u2013273. https:\/\/doi.org\/10.1007\/s11060-011-0575-8","journal-title":"J Neurooncol"},{"key":"5768_CR115","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1158\/ajc.1938.333","volume":"34","author":"HJ Scherer","year":"1938","unstructured":"Scherer HJ (1938) Structural Development in Gliomas. Am J Cancer 34:333\u2013351. https:\/\/doi.org\/10.1158\/ajc.1938.333","journal-title":"Am J Cancer"},{"key":"5768_CR116","doi-asserted-by":"publisher","first-page":"1635","DOI":"10.1200\/JCO.2002.20.6.1635","volume":"20","author":"JL Chan","year":"2002","unstructured":"Chan JL, Lee SW, Fraass BA, Normolle DP, Greenberg HS, Junck LR et al (2002) Survival and failure patterns of high-grade gliomas after three-dimensional conformal radiotherapy. J Clin Oncol 20:1635\u20131642. https:\/\/doi.org\/10.1200\/JCO.2002.20.6.1635","journal-title":"J Clin Oncol"},{"key":"5768_CR117","doi-asserted-by":"publisher","first-page":"864","DOI":"10.1038\/s41598-023-51063-7","volume":"14","author":"RK Gupta","year":"2024","unstructured":"Gupta RK, Niklasson M, Bergstr\u00f6m T, Segerman A, Betsholtz C, Westermark B (2024) Tumor-specific migration routes of xenotransplanted human glioblastoma cells in mouse brain. Sci Rep Nat Publishing Group 14:864. https:\/\/doi.org\/10.1038\/s41598-023-51063-7","journal-title":"Sci Rep Nat Publishing Group"},{"key":"5768_CR118","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1007\/s11060-013-1049-y","volume":"112","author":"K Kallenberg","year":"2013","unstructured":"Kallenberg K, Goldmann T, Menke J, Strik H, Bock HC, Stockhammer F et al (2013) Glioma infiltration of the corpus callosum: early signs detected by DTI. J Neurooncol 112:217\u2013222. https:\/\/doi.org\/10.1007\/s11060-013-1049-y","journal-title":"J Neurooncol"},{"key":"5768_CR119","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1002\/glia.20334","volume":"53","author":"A Farin","year":"2006","unstructured":"Farin A, Suzuki SO, Weiker M, Goldman JE, Bruce JN, Canoll P (2006) Transplanted glioma cells migrate and proliferate on host brain vasculature: a dynamic analysis. Glia 53:799\u2013808. https:\/\/doi.org\/10.1002\/glia.20334","journal-title":"Glia"},{"key":"5768_CR120","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1212\/wnl.30.9.907","volume":"30","author":"FH Hochberg","year":"1980","unstructured":"Hochberg FH, Pruitt A (1980) Assumptions in the radiotherapy of glioblastoma. Neurology 30:907\u2013911. https:\/\/doi.org\/10.1212\/wnl.30.9.907","journal-title":"Neurology"},{"key":"5768_CR121","doi-asserted-by":"publisher","first-page":"1405","DOI":"10.1016\/0360-3016(89)90941-3","volume":"16","author":"KE Wallner","year":"1989","unstructured":"Wallner KE, Galicich JH, Krol G, Arbit E, Malkin MG (1989) Patterns of failure following treatment for glioblastoma multiforme and anaplastic astrocytoma. Int J Radiat Oncol Biol Phys 16:1405\u20131409. https:\/\/doi.org\/10.1016\/0360-3016(89)90941-3","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"5768_CR122","doi-asserted-by":"publisher","first-page":"525","DOI":"10.3171\/jns.1997.86.3.0525","volume":"86","author":"DL Silbergeld","year":"1997","unstructured":"Silbergeld DL, Chicoine MR (1997) Isolation and characterization of human malignant glioma cells from histologically normal brain. J Neurosurg 86:525\u2013531. https:\/\/doi.org\/10.3171\/jns.1997.86.3.0525","journal-title":"J Neurosurg"},{"key":"5768_CR123","doi-asserted-by":"publisher","first-page":"698","DOI":"10.3171\/jns.1988.68.5.0698","volume":"68","author":"PC Burger","year":"1988","unstructured":"Burger PC, Heinz ER, Shibata T, Kleihues P (1988) Topographic anatomy and CT correlations in the untreated glioblastoma multiforme. J Neurosurg 68:698\u2013704. https:\/\/doi.org\/10.3171\/jns.1988.68.5.0698","journal-title":"J Neurosurg"},{"key":"5768_CR124","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1215\/15228517-2007-023","volume":"9","author":"DA Lim","year":"2007","unstructured":"Lim DA, Cha S, Mayo MC, Chen M-H, Keles E, VandenBerg S et al (2007) Relationship of glioblastoma multiforme to neural stem cell regions predicts invasive and multifocal tumor phenotype. Neuro Oncol 9:424\u2013429. https:\/\/doi.org\/10.1215\/15228517-2007-023","journal-title":"Neuro Oncol"},{"key":"5768_CR125","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1016\/j.neo.2014.06.003","volume":"16","author":"GJ Baker","year":"2014","unstructured":"Baker GJ, Yadav VN, Motsch S, Koschmann C, Calinescu A-A, Mineharu Y et al (2014) Mechanisms of Glioma Formation: Iterative Perivascular Glioma Growth and Invasion Leads to Tumor Progression, VEGF-Independent Vascularization, and Resistance to Antiangiogenic Therapy. Neoplasia 16:543\u2013561. https:\/\/doi.org\/10.1016\/j.neo.2014.06.003","journal-title":"Neoplasia"},{"key":"5768_CR126","doi-asserted-by":"publisher","first-page":"19208","DOI":"10.1038\/s41598-022-23794-6","volume":"12","author":"M Hazaymeh","year":"2022","unstructured":"Hazaymeh M, L\u00f6ber-Handwerker R, D\u00f6ring K, Abboud T, Mielke D, Rohde V et al (2022) Prognostic differences and implications on treatment strategies between butterfly glioblastoma and glioblastoma with unilateral corpus callosum infiltration. Sci Rep 12:19208. https:\/\/doi.org\/10.1038\/s41598-022-23794-6","journal-title":"Sci Rep"},{"key":"5768_CR127","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1093\/neuonc\/noz216","volume":"22","author":"MR Drumm","year":"2020","unstructured":"Drumm MR, Dixit KS, Grimm S, Kumthekar P, Lukas RV, Raizer JJ et al (2020) Extensive brainstem infiltration, not mass effect, is a common feature of end-stage cerebral glioblastomas. Neurooncology 22:470\u2013479. https:\/\/doi.org\/10.1093\/neuonc\/noz216","journal-title":"Neurooncology"},{"key":"5768_CR128","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1007\/s11060-026-05734-w","volume":"179","author":"R Chojak","year":"2026","unstructured":"Chojak R, Drewes NB, Slychan K, Lukas RV (2026) Spatial patterns of progression in reported glioblastoma cohorts after upfront chemoradiation and salvage therapy: a systematic review and meta-analysis. J Neurooncol 179:20. https:\/\/doi.org\/10.1007\/s11060-026-05734-w","journal-title":"J Neurooncol"},{"key":"5768_CR129","doi-asserted-by":"publisher","first-page":"1246","DOI":"10.1039\/c6ib00167j","volume":"8","author":"KM Kingsmore","year":"2016","unstructured":"Kingsmore KM, Logsdon DK, Floyd DH, Peirce SM, Purow BW, Munson JM (2016) Interstitial flow differentially increases patient-derived glioblastoma stem cell invasion via CXCR4, CXCL12, and CD44-mediated mechanisms. Integr Biol (Camb) 8:1246\u20131260. https:\/\/doi.org\/10.1039\/c6ib00167j","journal-title":"Integr Biol (Camb)"},{"key":"5768_CR130","doi-asserted-by":"publisher","first-page":"1536","DOI":"10.1158\/0008-5472.CAN-12-2838","volume":"73","author":"JM Munson","year":"2013","unstructured":"Munson JM, Bellamkonda RV, Swartz MA (2013) Interstitial Flow in a 3D Microenvironment Increases Glioma Invasion by a CXCR4-Dependent Mechanism. Cancer Res 73:1536\u20131546. https:\/\/doi.org\/10.1158\/0008-5472.CAN-12-2838","journal-title":"Cancer Res"},{"key":"5768_CR131","doi-asserted-by":"publisher","first-page":"24552","DOI":"10.1038\/srep24552","volume":"6","author":"S-H Ahn","year":"2016","unstructured":"Ahn S-H, Park H, Ahn Y-H, Kim S, Cho M-S, Kang JL et al (2016) Necrotic cells influence migration and invasion of glioblastoma via NF-\u03baB\/AP-1-mediated IL-8 regulation. Sci Rep 6:24552. https:\/\/doi.org\/10.1038\/srep24552","journal-title":"Sci Rep"},{"key":"5768_CR132","doi-asserted-by":"publisher","first-page":"9069","DOI":"10.1038\/s41598-019-45535-y","volume":"9","author":"MG McCoy","year":"2019","unstructured":"McCoy MG, Nyanyo D, Hung CK, Goerger JP, Zipfel R, Williams W (2019) Endothelial cells promote 3D invasion of GBM by IL-8-dependent induction of cancer stem cell properties. Sci Rep Nat Publishing Group 9:9069. https:\/\/doi.org\/10.1038\/s41598-019-45535-y","journal-title":"Sci Rep Nat Publishing Group"},{"key":"5768_CR133","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1007\/s11060-010-0261-2","volume":"101","author":"B Raychaudhuri","year":"2011","unstructured":"Raychaudhuri B, Vogelbaum MA (2011) IL-8 is a mediator of NF-\u03baB induced invasion by gliomas. J Neurooncol 101:227\u2013235. https:\/\/doi.org\/10.1007\/s11060-010-0261-2","journal-title":"J Neurooncol"},{"key":"5768_CR134","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1093\/neuonc\/noz189","volume":"22","author":"C Yu-Ju Wu","year":"2020","unstructured":"Yu-Ju Wu C, Chen C-H, Lin C-Y, Feng L-Y, Lin Y-C, Wei K-C et al (2020) CCL5 of glioma-associated microglia\/macrophages regulates glioma migration and invasion via calcium-dependent matrix metalloproteinase 2. Neuro Oncol 22:253\u2013266. https:\/\/doi.org\/10.1093\/neuonc\/noz189","journal-title":"Neuro Oncol"},{"key":"5768_CR135","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1038\/s41374-019-0345-3","volume":"100","author":"X Zhang","year":"2020","unstructured":"Zhang X, Chen L, Dang W-Q, Cao M-F, Xiao J-F, Lv S-Q et al (2020) CCL8 secreted by tumor-associated macrophages promotes invasion and stemness of glioblastoma cells via ERK1\/2 signaling. Lab Invest 100:619\u2013629. https:\/\/doi.org\/10.1038\/s41374-019-0345-3","journal-title":"Lab Invest"},{"key":"5768_CR136","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1093\/neuonc\/nop076","volume":"12","author":"G Scium\u00e8","year":"2010","unstructured":"Scium\u00e8 G, Soriani A, Piccoli M, Frati L, Santoni A, Bernardini G (2010) CX3CR1\/CX3CL1 axis negatively controls glioma cell invasion and is modulated by transforming growth factor-beta1. Neuro Oncol 12:701\u2013710. https:\/\/doi.org\/10.1093\/neuonc\/nop076","journal-title":"Neuro Oncol"},{"key":"5768_CR137","doi-asserted-by":"publisher","first-page":"1277","DOI":"10.1200\/JCO.1990.8.7.1277","volume":"8","author":"DR Macdonald","year":"1990","unstructured":"Macdonald DR, Cascino TL, Schold SC, Cairncross JG (1990) Response criteria for phase II studies of supratentorial malignant glioma. J Clin Oncol 8:1277\u20131280. https:\/\/doi.org\/10.1200\/JCO.1990.8.7.1277","journal-title":"J Clin Oncol"},{"key":"5768_CR138","doi-asserted-by":"publisher","first-page":"1963","DOI":"10.1200\/JCO.2009.26.3541","volume":"28","author":"PY Wen","year":"2010","unstructured":"Wen PY, Macdonald DR, Reardon DA, Cloughesy TF, Sorensen AG, Galanis E et al (2010) Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group. J Clin Oncol 28:1963\u20131972. https:\/\/doi.org\/10.1200\/JCO.2009.26.3541","journal-title":"J Clin Oncol"},{"key":"5768_CR139","doi-asserted-by":"publisher","first-page":"5187","DOI":"10.1200\/JCO.23.01059","volume":"41","author":"PY Wen","year":"2023","unstructured":"Wen PY, van den Bent M, Youssef G, Cloughesy TF, Ellingson BM, Weller M et al (2023) RANO 2.0: Update to the Response Assessment in Neuro-Oncology Criteria for High- and Low-Grade Gliomas in Adults. J Clin Oncol 41:5187\u20135199. https:\/\/doi.org\/10.1200\/JCO.23.01059","journal-title":"J Clin Oncol"},{"key":"5768_CR140","doi-asserted-by":"publisher","first-page":"1100","DOI":"10.1016\/S1470-2045(14)70379-1","volume":"15","author":"R Stupp","year":"2014","unstructured":"Stupp R, Hegi ME, Gorlia T, Erridge SC, Perry J, Hong Y-K et al (2014) Cilengitide combined with standard treatment for patients with newly diagnosed glioblastoma with methylated MGMT promoter (CENTRIC EORTC 26071\u2009\u2013\u200922072 study): a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol 15:1100\u20131108. https:\/\/doi.org\/10.1016\/S1470-2045(14)70379-1","journal-title":"Lancet Oncol"},{"key":"5768_CR141","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1186\/1756-9966-27-86","volume":"27","author":"L Oliveira-Ferrer","year":"2008","unstructured":"Oliveira-Ferrer L, Hauschild J, Fiedler W, Bokemeyer C, Nippgen J, Celik I et al (2008) Cilengitide induces cellular detachment and apoptosis in endothelial and glioma cells mediated by inhibition of FAK\/src\/AKT pathway. J Exp Clin Cancer Res 27:86. https:\/\/doi.org\/10.1186\/1756-9966-27-86","journal-title":"J Exp Clin Cancer Res"},{"key":"5768_CR142","doi-asserted-by":"publisher","first-page":"1651","DOI":"10.1200\/JCO.2006.06.6514","volume":"25","author":"LB Nabors","year":"2007","unstructured":"Nabors LB, Mikkelsen T, Rosenfeld SS, Hochberg F, Akella NS, Fisher JD et al (2007) Phase I and correlative biology study of cilengitide in patients with recurrent malignant glioma. J Clin Oncol 25:1651\u20131657. https:\/\/doi.org\/10.1200\/JCO.2006.06.6514","journal-title":"J Clin Oncol"},{"key":"5768_CR143","doi-asserted-by":"publisher","first-page":"5610","DOI":"10.1200\/JCO.2008.16.7510","volume":"26","author":"DA Reardon","year":"2008","unstructured":"Reardon DA, Fink KL, Mikkelsen T, Cloughesy TF, O\u2019Neill A, Plotkin S et al (2008) Randomized phase II study of cilengitide, an integrin-targeting arginine-glycine-aspartic acid peptide, in recurrent glioblastoma multiforme. J Clin Oncol 26:5610\u20135617. https:\/\/doi.org\/10.1200\/JCO.2008.16.7510","journal-title":"J Clin Oncol"},{"key":"5768_CR144","doi-asserted-by":"publisher","first-page":"2445","DOI":"10.1016\/j.celrep.2016.10.052","volume":"17","author":"RL Bowman","year":"2016","unstructured":"Bowman RL, Klemm F, Akkari L, Pyonteck SM, Sevenich L, Quail DF et al (2016) Macrophage Ontogeny Underlies Differences in Tumor-Specific Education in Brain Malignancies. Cell Rep 17:2445\u20132459. https:\/\/doi.org\/10.1016\/j.celrep.2016.10.052","journal-title":"Cell Rep"},{"key":"5768_CR145","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1186\/s13059-017-1362-4","volume":"18","author":"S M\u00fcller","year":"2017","unstructured":"M\u00fcller S, Kohanbash G, Liu SJ, Alvarado B, Carrera D, Bhaduri A et al (2017) Single-cell profiling of human gliomas reveals macrophage ontogeny as a basis for regional differences in macrophage activation in the tumor microenvironment. Genome Biol Springer Sci Bus Media LLC 18:234. https:\/\/doi.org\/10.1186\/s13059-017-1362-4","journal-title":"Genome Biol Springer Sci Bus Media LLC"},{"key":"5768_CR146","doi-asserted-by":"publisher","first-page":"1643","DOI":"10.1016\/j.cell.2020.05.007","volume":"181","author":"F Klemm","year":"2020","unstructured":"Klemm F, Maas RR, Bowman RL, Kornete M, Soukup K, Nassiri S et al (2020) Interrogation of the Microenvironmental Landscape in Brain Tumors Reveals Disease-Specific Alterations of Immune Cells. Cell 181:1643\u20131660e17. https:\/\/doi.org\/10.1016\/j.cell.2020.05.007","journal-title":"Cell"},{"key":"5768_CR147","doi-asserted-by":"publisher","first-page":"1626","DOI":"10.1016\/j.cell.2020.04.055","volume":"181","author":"E Friebel","year":"2020","unstructured":"Friebel E, Kapolou K, Unger S, N\u00fa\u00f1ez NG, Utz S, Rushing EJ et al (2020) Single-Cell Mapping of Human Brain Cancer Reveals Tumor-Specific Instruction of Tissue-Invading Leukocytes. Cell Elsevier BV 181:1626\u20131642e20. https:\/\/doi.org\/10.1016\/j.cell.2020.04.055","journal-title":"Cell Elsevier BV"},{"key":"5768_CR148","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1038\/s41467-022-28372-y","volume":"13","author":"N Abdelfattah","year":"2022","unstructured":"Abdelfattah N, Kumar P, Wang C, Leu J-S, Flynn WF, Gao R et al (2022) Single-cell analysis of human glioma and immune cells identifies S100A4 as an immunotherapy target. Nat Commun Nat Publishing Group 13:767. https:\/\/doi.org\/10.1038\/s41467-022-28372-y","journal-title":"Nat Commun Nat Publishing Group"},{"key":"5768_CR149","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1038\/s41467-022-28523-1","volume":"13","author":"VM Ravi","year":"2022","unstructured":"Ravi VM, Neidert N, Will P, Joseph K, Maier JP, K\u00fcckelhaus J et al (2022) T-cell dysfunction in the glioblastoma microenvironment is mediated by myeloid cells releasing interleukin-10. Nat Commun Nat Publishing Group 13:925. https:\/\/doi.org\/10.1038\/s41467-022-28523-1","journal-title":"Nat Commun Nat Publishing Group"},{"key":"5768_CR150","doi-asserted-by":"publisher","first-page":"4814","DOI":"10.1038\/s41467-022-32430-w","volume":"13","author":"S Coy","year":"2022","unstructured":"Coy S, Wang S, Stopka SA, Lin J-R, Yapp C, Ritch CC et al (2022) Single cell spatial analysis reveals the topology of immunomodulatory purinergic signaling in glioblastoma. Nat Commun Nat Publishing Group 13:4814. https:\/\/doi.org\/10.1038\/s41467-022-32430-w","journal-title":"Nat Commun Nat Publishing Group"},{"key":"5768_CR151","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1038\/s41593-020-00789-y","volume":"24","author":"AR Pombo Antunes","year":"2021","unstructured":"Pombo Antunes AR, Scheyltjens I, Lodi F, Messiaen J, Antoranz A, Duerinck J et al (2021) Single-cell profiling of myeloid cells in glioblastoma across species and disease stage reveals macrophage competition and specialization. Nat Neurosci 24:595\u2013610. https:\/\/doi.org\/10.1038\/s41593-020-00789-y","journal-title":"Nat Neurosci"},{"key":"5768_CR152","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1038\/s41586-022-05680-3","volume":"614","author":"E Karimi","year":"2023","unstructured":"Karimi E, Yu MW, Maritan SM, Perus LJM, Rezanejad M, Sorin M et al (2023) Single-cell spatial immune landscapes of primary and metastatic brain tumours. Nat Nat Publishing Group 614:555\u2013563. https:\/\/doi.org\/10.1038\/s41586-022-05680-3","journal-title":"Nat Nat Publishing Group"},{"key":"5768_CR153","doi-asserted-by":"publisher","first-page":"eadj3301","DOI":"10.1126\/sciadv.adj3301","volume":"10","author":"MJ Haley","year":"2024","unstructured":"Haley MJ, Bere L, Minshull J, Georgaka S, Garcia-Martin N, Howell G et al (2024) Hypoxia coordinates the spatial landscape of myeloid cells within glioblastoma to affect survival. Sci Adv Am Association Advancement Sci 10:eadj3301. https:\/\/doi.org\/10.1126\/sciadv.adj3301","journal-title":"Sci Adv Am Association Advancement Sci"},{"key":"5768_CR154","doi-asserted-by":"publisher","first-page":"1072","DOI":"10.1038\/s41586-025-08633-8","volume":"640","author":"TE Miller","year":"2025","unstructured":"Miller TE, El Farran CA, Couturier CP, Chen Z, D\u2019Antonio JP, Verga J et al (2025) Programs, origins and immunomodulatory functions of myeloid cells in glioma. Nat Springer Sci Bus Media LLC 640:1072\u20131082. https:\/\/doi.org\/10.1038\/s41586-025-08633-8","journal-title":"Nat Springer Sci Bus Media LLC"},{"key":"5768_CR155","doi-asserted-by":"publisher","first-page":"eabm5214","DOI":"10.1126\/science.abm5214","volume-title":"Distinct myeloid-derived suppressor cell populations in human glioblastoma","author":"C Jackson","year":"2025","unstructured":"Jackson C, Cherry C, Bom S, Dykema AG, Wang R, Thompson E et al (2025) Distinct myeloid-derived suppressor cell populations in human glioblastoma, vol 387. Science, New York, N, p eabm5214. https:\/\/doi.org\/10.1126\/science.abm5214"},{"key":"5768_CR156","doi-asserted-by":"publisher","first-page":"1825","DOI":"10.1016\/j.immuni.2023.06.017","volume":"56","author":"A Sattiraju","year":"2023","unstructured":"Sattiraju A, Kang S, Giotti B, Chen Z, Marallano VJ, Brusco C et al (2023) Hypoxic niches attract and sequester tumor-associated macrophages and cytotoxic T cells and reprogram them for immunosuppression. Immunity 56:1825\u20131843e6. https:\/\/doi.org\/10.1016\/j.immuni.2023.06.017","journal-title":"Immunity"},{"key":"5768_CR157","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1016\/j.cell.2023.11.032","volume":"187","author":"D Kirschenbaum","year":"2024","unstructured":"Kirschenbaum D, Xie K, Ingelfinger F, Katzenelenbogen Y, Abadie K, Look T et al (2024) Time-resolved single-cell transcriptomics defines immune trajectories in glioblastoma. Cell 187:149\u2013165e23. https:\/\/doi.org\/10.1016\/j.cell.2023.11.032","journal-title":"Cell"},{"key":"5768_CR158","doi-asserted-by":"publisher","first-page":"1129","DOI":"10.1073\/pnas.1910856117","volume":"117","author":"JA Flores-Toro","year":"2020","unstructured":"Flores-Toro JA, Luo D, Gopinath A, Sarkisian MR, Campbell JJ, Charo IF et al (2020) CCR2 inhibition reduces tumor myeloid cells and unmasks a checkpoint inhibitor effect to slow progression of resistant murine gliomas. Proc Natl Acad Sci U S A 117:1129\u20131138. https:\/\/doi.org\/10.1073\/pnas.1910856117","journal-title":"Proc Natl Acad Sci U S A"},{"key":"5768_CR159","doi-asserted-by":"publisher","first-page":"2338965","DOI":"10.1080\/2162402X.2024.2338965","volume":"13","author":"A Pant","year":"2024","unstructured":"Pant A, Hwa-Lin Bergsneider B, Srivastava S, Kim T, Jain A, Bom S et al (2024) CCR2 and CCR5 co-inhibition modulates immunosuppressive myeloid milieu in glioma and synergizes with anti-PD-1 therapy. OncoImmunology Taylor Francis 13:2338965. https:\/\/doi.org\/10.1080\/2162402X.2024.2338965","journal-title":"OncoImmunology Taylor Francis"},{"key":"5768_CR160","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1016\/j.ccell.2023.03.004","volume":"41","author":"H Liu","year":"2023","unstructured":"Liu H, Zhao Q, Tan L, Wu X, Huang R, Zuo Y et al (2023) Neutralizing IL-8 potentiates immune checkpoint blockade efficacy for glioma. Cancer Cell 41:693\u2013710e8. https:\/\/doi.org\/10.1016\/j.ccell.2023.03.004","journal-title":"Cancer Cell"},{"key":"5768_CR161","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1007\/s00262-007-0336-x","volume":"57","author":"JT Jordan","year":"2007","unstructured":"Jordan JT, Sun W, Hussain SF, DeAngulo G, Prabhu SS, Heimberger AB (2007) Preferential migration of regulatory T cells mediated by glioma-secreted chemokines can be blocked with chemotherapy. Cancer Immunol Immunother 57:123\u2013131. https:\/\/doi.org\/10.1007\/s00262-007-0336-x","journal-title":"Cancer Immunol Immunother"},{"key":"5768_CR162","doi-asserted-by":"publisher","first-page":"5871","DOI":"10.1038\/s41467-024-49989-1","volume":"15","author":"CA von Roemeling","year":"2024","unstructured":"von Roemeling CA, Patel JA, Carpenter SL, Yegorov O, Yang C, Bhatia A et al (2024) Adeno-associated virus delivered CXCL9 sensitizes glioblastoma to anti-PD-1 immune checkpoint blockade. Nat Commun Nat Publishing Group 15:5871. https:\/\/doi.org\/10.1038\/s41467-024-49989-1","journal-title":"Nat Commun Nat Publishing Group"},{"key":"5768_CR163","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1038\/s41590-022-01215-0","volume":"23","author":"AT Yeo","year":"2022","unstructured":"Yeo AT, Rawal S, Delcuze B, Christofides A, Atayde A, Strauss L et al (2022) Single-cell RNA sequencing reveals evolution of immune landscape during glioblastoma progression. Nat Immunol 23:971\u2013984. https:\/\/doi.org\/10.1038\/s41590-022-01215-0","journal-title":"Nat Immunol"},{"key":"5768_CR164","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1038\/s41571-021-00518-9","volume":"18","author":"M Ott","year":"2021","unstructured":"Ott M, Prins RM, Heimberger AB (2021) The immune landscape of common CNS malignancies: implications for immunotherapy. Nat Rev Clin Oncol 18:729\u2013744. https:\/\/doi.org\/10.1038\/s41571-021-00518-9","journal-title":"Nat Rev Clin Oncol"},{"key":"5768_CR165","doi-asserted-by":"publisher","first-page":"103079","DOI":"10.1016\/j.xpro.2024.103079","volume":"5","author":"H Najem","year":"2024","unstructured":"Najem H, Pacheco S, Kowal J, Winkowski D, Burks JK, Heimberger AB (2024) Protocol to quantify immune cell distribution from the vasculature to the glioma microenvironment on sequential immunofluorescence multiplex images. STAR Protoc 5:103079. https:\/\/doi.org\/10.1016\/j.xpro.2024.103079","journal-title":"STAR Protoc"},{"key":"5768_CR166","doi-asserted-by":"publisher","first-page":"3565","DOI":"10.1158\/1078-0432.CCR-20-0176","volume":"26","author":"S-P Weathers","year":"2020","unstructured":"Weathers S-P, Penas-Prado M, Pei B-L, Ling X, Kassab C, Banerjee P et al (2020) Glioblastoma-mediated Immune Dysfunction Limits CMV-specific T Cells and Therapeutic Responses: Results from a Phase I\/II Trial. Clin Cancer Res 26:3565\u20133577. https:\/\/doi.org\/10.1158\/1078-0432.CCR-20-0176","journal-title":"Clin Cancer Res"},{"key":"5768_CR167","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1007\/s13402-022-00763-9","volume":"46","author":"M Dinevska","year":"2023","unstructured":"Dinevska M, Widodo SS, Furst L, Cuzcano L, Fang Y, Mangiola S et al (2023) Cell signaling activation and extracellular matrix remodeling underpin glioma tumor microenvironment heterogeneity and organization. Cell Oncol 46:589\u2013602. https:\/\/doi.org\/10.1007\/s13402-022-00763-9","journal-title":"Cell Oncol"},{"key":"5768_CR168","doi-asserted-by":"publisher","first-page":"993444","DOI":"10.3389\/fimmu.2022.993444","volume":"13","author":"GP Takacs","year":"2023","unstructured":"Takacs GP, Kreiger CJ, Luo D, Tian G, Garcia JS, Deleyrolle LP et al (2023) Glioma-derived CCL2 and CCL7 mediate migration of immune suppressive CCR2+\/CX3CR1\u2009+\u2009M-MDSCs into the tumor microenvironment in a redundant manner. Front Immunol 13:993444. https:\/\/doi.org\/10.3389\/fimmu.2022.993444","journal-title":"Front Immunol"},{"key":"5768_CR169","doi-asserted-by":"publisher","first-page":"1308","DOI":"10.1093\/neuonc\/nor134","volume":"13","author":"DA Wainwright","year":"2011","unstructured":"Wainwright DA, Sengupta S, Han Y, Lesniak MS (2011) Thymus-derived rather than tumor-induced regulatory T cells predominate in brain tumors. Neuro Oncol 13:1308\u20131323. https:\/\/doi.org\/10.1093\/neuonc\/nor134","journal-title":"Neuro Oncol"},{"key":"5768_CR170","doi-asserted-by":"publisher","first-page":"aad3018","DOI":"10.1126\/science.aad3018","volume":"352","author":"DF Quail","year":"2016","unstructured":"Quail DF, Bowman RL, Akkari L, Quick ML, Schuhmacher AJ, Huse JT et al (2016) The tumor microenvironment underlies acquired resistance to CSF-1R inhibition in gliomas. Science 352:aad3018. https:\/\/doi.org\/10.1126\/science.aad3018","journal-title":"Science"},{"key":"5768_CR171","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1093\/neuonc\/nov245","volume":"18","author":"N Butowski","year":"2016","unstructured":"Butowski N, Colman H, De Groot JF, Omuro AM, Nayak L, Wen PY et al (2016) Orally administered colony-stimulating factor 1 receptor inhibitor PLX3397 in recurrent glioblastoma: an Ivy Foundation phase II study. Neuro Oncol 18:557\u2013564. https:\/\/doi.org\/10.1093\/neuonc\/nov245","journal-title":"Neuro Oncol"},{"key":"5768_CR172","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.1001\/jamaoncol.2020.1024","volume":"6","author":"DA Reardon","year":"2020","unstructured":"Reardon DA, Brandes AA, Omuro A, Mulholland P, Lim M, Wick A et al (2020) Effect of nivolumab vs bevacizumab in patients with recurrent glioblastoma: the CheckMate 143 phase 3 randomized clinical trial. JAMA Oncol 6:1003. https:\/\/doi.org\/10.1001\/jamaoncol.2020.1024","journal-title":"JAMA Oncol"},{"key":"5768_CR173","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1093\/neuonc\/noac099","volume":"25","author":"A Omuro","year":"2023","unstructured":"Omuro A, Brandes AA, Carpentier AF, Idbaih A, Reardon DA, Cloughesy T et al (2023) Radiotherapy combined with nivolumab or temozolomide for newly diagnosed glioblastoma with unmethylated MGMT promoter: CheckMate 498. Neurooncology 25:123\u2013134. https:\/\/doi.org\/10.1093\/neuonc\/noac099","journal-title":"Neurooncology"},{"key":"5768_CR174","doi-asserted-by":"publisher","first-page":"1935","DOI":"10.1093\/neuonc\/noac116","volume":"24","author":"M Lim","year":"2022","unstructured":"Lim M, Weller M, Idbaih A, Steinbach J, Finocchiaro G, Raval RR et al (2022) Phase III trial of chemoradiotherapy with temozolomide plus nivolumab or placebo for newly diagnosed glioblastoma with methylated MGMT promoter: CheckMate 548. Neurooncology 24:1935\u20131949. https:\/\/doi.org\/10.1093\/neuonc\/noac116","journal-title":"Neurooncology"},{"key":"5768_CR175","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1038\/s41591-018-0337-7","volume":"25","author":"TF Cloughesy","year":"2019","unstructured":"Cloughesy TF, Mochizuki AY, Orpilla JR, Hugo W, Lee AH, Davidson TB et al (2019) Neoadjuvant anti-PD-1 immunotherapy promotes a survival benefit with intratumoral and systemic immune responses in recurrent glioblastoma. Nat Med 25:477\u2013486. https:\/\/doi.org\/10.1038\/s41591-018-0337-7","journal-title":"Nat Med"},{"key":"5768_CR176","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1038\/s41591-018-0339-5","volume":"25","author":"KA Schalper","year":"2019","unstructured":"Schalper KA, Rodriguez-Ruiz ME, Diez-Valle R, L\u00f3pez-Janeiro A, Porciuncula A, Idoate MA et al (2019) Neoadjuvant nivolumab modifies the tumor immune microenvironment in resectable glioblastoma. Nat Med 25:470\u2013476. https:\/\/doi.org\/10.1038\/s41591-018-0339-5","journal-title":"Nat Med"},{"key":"5768_CR177","doi-asserted-by":"publisher","first-page":"10757","DOI":"10.1038\/s41467-024-54326-7","volume":"15","author":"JR McFaline-Figueroa","year":"2024","unstructured":"McFaline-Figueroa JR, Sun L, Youssef GC, Huang R, Li G, Kim J et al (2024) Neoadjuvant anti-PD1 immunotherapy for surgically accessible recurrent glioblastoma: clinical and molecular outcomes of a stage 2 single-arm expansion cohort. Nat Commun Nat Publishing Group 15:10757. https:\/\/doi.org\/10.1038\/s41467-024-54326-7","journal-title":"Nat Commun Nat Publishing Group"},{"key":"5768_CR178","doi-asserted-by":"publisher","first-page":"1048","DOI":"10.1158\/1078-0432.CCR-20-2500","volume":"27","author":"L Nayak","year":"2021","unstructured":"Nayak L, Molinaro AM, Peters K, Clarke JL, Jordan JT, de Groot J et al (2021) Randomized Phase II and Biomarker Study of Pembrolizumab plus Bevacizumab versus Pembrolizumab Alone for Patients with Recurrent Glioblastoma. Clin Cancer Res 27:1048\u20131057. https:\/\/doi.org\/10.1158\/1078-0432.CCR-20-2500","journal-title":"Clin Cancer Res"},{"key":"5768_CR179","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1093\/neuonc\/noz185","volume":"22","author":"J de Groot","year":"2020","unstructured":"de Groot J, Penas-Prado M, Alfaro-Munoz K, Hunter K, Pei BL, O\u2019Brien B et al (2020) Window-of-opportunity clinical trial of pembrolizumab in patients with recurrent glioblastoma reveals predominance of immune-suppressive macrophages. Neuro Oncol 22:539\u2013549. https:\/\/doi.org\/10.1093\/neuonc\/noz185","journal-title":"Neuro Oncol"},{"key":"5768_CR180","doi-asserted-by":"publisher","first-page":"e178628","DOI":"10.1172\/JCI178628","volume":"134","author":"Y Liu","year":"2024","unstructured":"Liu Y, Wu J, Najem H, Lin Y, Pang L, Khan F et al (2024) Dual targeting macrophages and microglia is a therapeutic vulnerability in models of PTEN-deficient glioblastoma. J Clin Invest 134:e178628. https:\/\/doi.org\/10.1172\/JCI178628","journal-title":"J Clin Invest"},{"key":"5768_CR181","doi-asserted-by":"publisher","first-page":"6938","DOI":"10.1038\/s41467-021-26940-2","volume":"12","author":"AH Lee","year":"2021","unstructured":"Lee AH, Sun L, Mochizuki AY, Reynoso JG, Orpilla J, Chow F et al (2021) Neoadjuvant PD-1 blockade induces T cell and cDC1 activation but fails to overcome the immunosuppressive tumor associated macrophages in recurrent glioblastoma. Nat Commun Nat Publishing Group 12:6938. https:\/\/doi.org\/10.1038\/s41467-021-26940-2","journal-title":"Nat Commun Nat Publishing Group"},{"key":"5768_CR182","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1038\/s41586-025-08997-x","volume":"643","author":"C Faust Akl","year":"2025","unstructured":"Faust Akl C, Andersen BM, Li Z, Giovannoni F, Diebold M, Sanmarco LM et al (2025) Glioblastoma-instructed astrocytes suppress tumour-specific T cell immunity. Nat Springer Sci Bus Media LLC 643:219\u2013229. https:\/\/doi.org\/10.1038\/s41586-025-08997-x","journal-title":"Nat Springer Sci Bus Media LLC"},{"key":"5768_CR183","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1158\/1078-0432.ccr-20-2291","volume":"27","author":"JB Iorgulescu","year":"2021","unstructured":"Iorgulescu JB, Gokhale PC, Speranza MC, Eschle BK, Poitras MJ, Wilkens MK et al (2021) Concurrent dexamethasone limits the clinical benefit of immune checkpoint blockade in glioblastoma. Clin Cancer Res 27:276\u2013287. https:\/\/doi.org\/10.1158\/1078-0432.ccr-20-2291","journal-title":"Clin Cancer Res"},{"key":"5768_CR184","doi-asserted-by":"publisher","first-page":"71","DOI":"10.14791\/btrt.2020.8.e12","volume":"8","author":"C Lee","year":"2020","unstructured":"Lee C, Ahn S, Park J-S, Song JH, Hong Y-K, Jeun S-S (2020) Effect of Cumulative Dexamethasone Dose during Concomitant Chemoradiation on Lymphopenia in Patients with Newly Diagnosed Glioblastoma. Brain Tumor Res Treat 8:71\u201376. https:\/\/doi.org\/10.14791\/btrt.2020.8.e12","journal-title":"Brain Tumor Res Treat"},{"key":"5768_CR185","doi-asserted-by":"publisher","first-page":"e27357","DOI":"10.4161\/onci.27357","volume":"3","author":"S Ellsworth","year":"2014","unstructured":"Ellsworth S, Balmanoukian A, Kos F, Nirschl CJ, Nirschl TR, Grossman SA et al (2014) Sustained CD4\u2009+\u2009T cell-driven lymphopenia without a compensatory IL-7\/IL-15 response among high-grade glioma patients treated with radiation and temozolomide. Oncoimmunology 3:e27357. https:\/\/doi.org\/10.4161\/onci.27357","journal-title":"Oncoimmunology"},{"key":"5768_CR186","doi-asserted-by":"publisher","first-page":"e002181","DOI":"10.1136\/jitc-2020-002181","volume":"9","author":"EF Simonds","year":"2021","unstructured":"Simonds EF, Lu ED, Badillo O, Karimi S, Liu EV, Tamaki W et al (2021) Deep immune profiling reveals targetable mechanisms of immune evasion in immune checkpoint inhibitor-refractory glioblastoma. J Immunother Cancer 9:e002181. https:\/\/doi.org\/10.1136\/jitc-2020-002181","journal-title":"J Immunother Cancer"},{"key":"5768_CR187","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1016\/j.ccell.2022.12.007","volume":"41","author":"M Kilian","year":"2023","unstructured":"Kilian M, Sheinin R, Tan CL, Friedrich M, Kr\u00e4mer C, Kaminitz A et al (2023) MHC class II-restricted antigen presentation is required to prevent dysfunction of cytotoxic T cells by blood-borne myeloids in brain tumors. Cancer Cell 41:235\u2013251e9. https:\/\/doi.org\/10.1016\/j.ccell.2022.12.007","journal-title":"Cancer Cell"},{"key":"5768_CR188","doi-asserted-by":"publisher","first-page":"1987","DOI":"10.1038\/s41467-024-46193-z","volume":"15","author":"F Khan","year":"2024","unstructured":"Khan F, Lin Y, Ali H, Pang L, Dunterman M, Hsu W-H et al (2024) Lactate dehydrogenase A regulates tumor-macrophage symbiosis to promote glioblastoma progression. Nat Commun 15:1987. https:\/\/doi.org\/10.1038\/s41467-024-46193-z","journal-title":"Nat Commun"},{"key":"5768_CR189","doi-asserted-by":"publisher","first-page":"3070","DOI":"10.1038\/s41388-018-0182-7","volume":"37","author":"P Jin","year":"2018","unstructured":"Jin P, Shin S-H, Chun Y-S, Shin H-W, Shin YJ, Lee Y et al (2018) Astrocyte-derived CCL20 reinforces HIF-1-mediated hypoxic responses in glioblastoma by stimulating the CCR6-NF-\u03baB signaling pathway. Oncogene 37:3070\u20133087. https:\/\/doi.org\/10.1038\/s41388-018-0182-7","journal-title":"Oncogene"},{"key":"5768_CR190","doi-asserted-by":"publisher","first-page":"e176851","DOI":"10.1172\/JCI176851","volume":"134","author":"S Wang","year":"2024","unstructured":"Wang S, Huang T, Wu Q, Yuan H, Wu X, Yuan F et al (2024) Lactate reprograms glioblastoma immunity through CBX3-regulated histone lactylation. J Clin Invest 134:e176851. https:\/\/doi.org\/10.1172\/JCI176851","journal-title":"J Clin Invest"},{"key":"5768_CR191","doi-asserted-by":"publisher","first-page":"1105","DOI":"10.1016\/j.immuni.2024.04.006","volume":"57","author":"A De Leo","year":"2024","unstructured":"De Leo A, Ugolini A, Yu X, Scirocchi F, Scocozza D, Peixoto B et al (2024) Glucose-driven histone lactylation promotes the immunosuppressive activity of monocyte-derived macrophages in glioblastoma. Immunity 57:1105\u20131123e8. https:\/\/doi.org\/10.1016\/j.immuni.2024.04.006","journal-title":"Immunity"},{"key":"5768_CR192","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1038\/s43018-023-00658-0","volume":"5","author":"L Zhao","year":"2024","unstructured":"Zhao L, Qiu Z, Yang Z, Xu L, Pearce TM, Wu Q et al (2024) Lymphatic endothelial-like cells promote glioblastoma stem cell growth through cytokine-driven cholesterol metabolism. Nat Cancer 5:147\u2013166. https:\/\/doi.org\/10.1038\/s43018-023-00658-0","journal-title":"Nat Cancer"},{"key":"5768_CR193","doi-asserted-by":"publisher","first-page":"1843","DOI":"10.3892\/ijo.2014.2382","volume":"44","author":"J Rieger","year":"2014","unstructured":"Rieger J, B\u00e4hr O, Maurer GD, Hattingen E, Franz K, Brucker D et al (2014) ERGO: A pilot study of ketogenic diet in recurrent glioblastoma Erratum in \/ijo\/45\/6\/2605. Int J Oncol Spandidos Publications 44:1843\u20131852. https:\/\/doi.org\/10.3892\/ijo.2014.2382","journal-title":"Int J Oncol Spandidos Publications"},{"key":"5768_CR194","doi-asserted-by":"publisher","first-page":"21064","DOI":"10.1038\/s41598-025-06675-6","volume":"15","author":"LJ Amaral","year":"2025","unstructured":"Amaral LJ, Gresham G, Kim S, Tighiouart M, Nelson TA, Welborn A et al (2025) A phase 1 safety and feasibility trial of a ketogenic diet plus standard of care for patients with recently diagnosed glioblastoma. Sci Rep 15:21064. https:\/\/doi.org\/10.1038\/s41598-025-06675-6","journal-title":"Sci Rep"},{"key":"5768_CR195","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1016\/j.stem.2016.11.003","volume":"20","author":"BB Liau","year":"2017","unstructured":"Liau BB, Sievers C, Donohue LK, Gillespie SM, Flavahan WA, Miller TE et al (2017) Adaptive Chromatin Remodeling Drives Glioblastoma Stem Cell Plasticity and Drug Tolerance. Cell Stem Cell 20:233\u2013246e7. https:\/\/doi.org\/10.1016\/j.stem.2016.11.003","journal-title":"Cell Stem Cell"},{"key":"5768_CR196","doi-asserted-by":"publisher","first-page":"1155","DOI":"10.1038\/s41588-025-02167-5","volume":"57","author":"M Nomura","year":"2025","unstructured":"Nomura M, Spitzer A, Johnson KC, Garofano L, Nehar-belaid D, Galili Darnell N et al (2025) The multilayered transcriptional architecture of glioblastoma ecosystems. Nat Genet Nat Publishing Group 57:1155\u20131167. https:\/\/doi.org\/10.1038\/s41588-025-02167-5","journal-title":"Nat Genet Nat Publishing Group"},{"key":"5768_CR197","doi-asserted-by":"publisher","first-page":"1168","DOI":"10.1038\/s41588-025-02168-4","volume":"57","author":"A Spitzer","year":"2025","unstructured":"Spitzer A, Johnson KC, Nomura M, Garofano L, Nehar-belaid D, Darnell NG et al (2025) Deciphering the longitudinal trajectories of glioblastoma ecosystems by integrative single-cell genomics. Nat Genet Nat Publishing Group 57:1168\u20131178. https:\/\/doi.org\/10.1038\/s41588-025-02168-4","journal-title":"Nat Genet Nat Publishing Group"},{"key":"5768_CR198","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1016\/j.ccr.2013.08.001","volume":"24","author":"KPL Bhat","year":"2013","unstructured":"Bhat KPL, Balasubramaniyan V, Vaillant B, Ezhilarasan R, Hummelink K, Hollingsworth F et al (2013) Mesenchymal Differentiation Mediated by NF-\u03baB Promotes Radiation Resistance in Glioblastoma. Cancer Cell 24:331\u2013346. https:\/\/doi.org\/10.1016\/j.ccr.2013.08.001","journal-title":"Cancer Cell"},{"key":"5768_CR199","doi-asserted-by":"publisher","first-page":"e64090","DOI":"10.7554\/eLife.64090","volume":"10","author":"P Guilhamon","year":"2021","unstructured":"Guilhamon P, Chesnelong C, Kushida MM, Nikolic A, Singhal D, MacLeod G et al (2021) Single-cell chromatin accessibility profiling of glioblastoma identifies an invasive cancer stem cell population associated with lower survival. Elife 10:e64090. https:\/\/doi.org\/10.7554\/eLife.64090","journal-title":"Elife"},{"key":"5768_CR200","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1016\/j.cell.2014.02.030","volume":"157","author":"ML Suv\u00e0","year":"2014","unstructured":"Suv\u00e0 ML, Rheinbay E, Gillespie SM, Patel AP, Wakimoto H, Rabkin SD et al (2014) Reconstructing and reprogramming the tumor-propagating potential of glioblastoma stem-like cells. Cell 157:580\u2013594. https:\/\/doi.org\/10.1016\/j.cell.2014.02.030","journal-title":"Cell"},{"key":"5768_CR201","doi-asserted-by":"publisher","first-page":"1342","DOI":"10.1038\/s41593-026-02265-5","volume":"29","author":"J Lin","year":"2026","unstructured":"Lin J, Chen C, Li S, Chen L, Fang M, Fu S et al (2026) Spatial and single-cell characterization of human glioblastoma tumor microenvironment reveals malignant cellular communities. Nat Neurosci Nat Publishing Group 29:1342\u20131354. https:\/\/doi.org\/10.1038\/s41593-026-02265-5","journal-title":"Nat Neurosci Nat Publishing Group"},{"key":"5768_CR202","doi-asserted-by":"publisher","first-page":"3779","DOI":"10.1158\/1078-0432.CCR-22-3273","volume":"29","author":"W Yuan","year":"2023","unstructured":"Yuan W, Zhang Q, Gu D, Lu C, Dixit D, Gimple RC et al (2023) Dual Role of CXCL8 in Maintaining the Mesenchymal State of Glioblastoma Stem Cells and M2-Like Tumor-Associated Macrophages. Clin Cancer Res 29:3779\u20133792. https:\/\/doi.org\/10.1158\/1078-0432.CCR-22-3273","journal-title":"Clin Cancer Res"},{"key":"5768_CR203","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1186\/1475-2867-13-85","volume":"13","author":"C-C Lee","year":"2013","unstructured":"Lee C-C, Lai J-H, Hueng D-Y, Ma H-I, Chung Y-C, Sun Y et al (2013) Disrupting the CXCL12\/CXCR4 axis disturbs the characteristics of glioblastoma stem-like cells of rat RG2 glioblastoma. Cancer Cell Int 13:85. https:\/\/doi.org\/10.1186\/1475-2867-13-85","journal-title":"Cancer Cell Int"},{"key":"5768_CR204","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1158\/0008-5472.CAN-18-1733","volume":"79","author":"D Aasland","year":"2019","unstructured":"Aasland D, G\u00f6tzinger L, Hauck L, Berte N, Meyer J, Effenberger M et al (2019) Temozolomide Induces Senescence and Repression of DNA Repair Pathways in Glioblastoma Cells via Activation of ATR\u2013CHK1, p21, and NF-\u03baB. Cancer Res 79:99\u2013113. https:\/\/doi.org\/10.1158\/0008-5472.CAN-18-1733","journal-title":"Cancer Res"},{"key":"5768_CR205","doi-asserted-by":"publisher","first-page":"e2304609","DOI":"10.1002\/advs.202304609","volume":"11","author":"J Ji","year":"2024","unstructured":"Ji J, Ding K, Cheng B, Zhang X, Luo T, Huang B et al (2024) Radiotherapy-Induced Astrocyte Senescence Promotes an Immunosuppressive Microenvironment in Glioblastoma to Facilitate Tumor Regrowth. Adv Sci (Weinh) 11:e2304609. https:\/\/doi.org\/10.1002\/advs.202304609","journal-title":"Adv Sci (Weinh)"},{"key":"5768_CR206","doi-asserted-by":"publisher","first-page":"2233","DOI":"10.3390\/cancers14092233","volume":"14","author":"L Beltzig","year":"2022","unstructured":"Beltzig L, Schwarzenbach C, Leukel P, Frauenknecht KBM, Sommer C, Tancredi A et al (2022) Senescence Is the Main Trait Induced by Temozolomide in Glioblastoma Cells. Cancers (Basel) 14:2233. https:\/\/doi.org\/10.3390\/cancers14092233","journal-title":"Cancers (Basel)"},{"key":"5768_CR207","doi-asserted-by":"publisher","first-page":"5857","DOI":"10.1007\/s13277-015-4439-2","volume":"37","author":"H-Y Jeon","year":"2016","unstructured":"Jeon H-Y, Kim J-K, Ham SW, Oh S-Y, Kim J, Park J-B et al (2016) Irradiation induces glioblastoma cell senescence and senescence-associated secretory phenotype. Tumour Biol 37:5857\u20135867. https:\/\/doi.org\/10.1007\/s13277-015-4439-2","journal-title":"Tumour Biol"},{"key":"5768_CR208","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1038\/s41467-023-36124-9","volume":"14","author":"R Salam","year":"2023","unstructured":"Salam R, Saliou A, Bielle F, Bertrand M, Antoniewski C, Carpentier C et al (2023) Cellular senescence in malignant cells promotes tumor progression in mouse and patient Glioblastoma. Nat Commun Nat Publishing Group 14:441. https:\/\/doi.org\/10.1038\/s41467-023-36124-9","journal-title":"Nat Commun Nat Publishing Group"},{"key":"5768_CR209","doi-asserted-by":"publisher","first-page":"5935","DOI":"10.1158\/0008-5472.CAN-21-0752","volume":"81","author":"E Fletcher-Sananikone","year":"2021","unstructured":"Fletcher-Sananikone E, Kanji S, Tomimatsu N, Cristofaro LFMD, Kollipara RK, Saha D et al (2021) Elimination of radiation-induced senescence in the brain tumor microenvironment attenuates glioblastoma recurrence. Cancer Res 81:5935\u20135947. https:\/\/doi.org\/10.1158\/0008-5472.CAN-21-0752","journal-title":"Cancer Res"},{"key":"5768_CR210","doi-asserted-by":"publisher","first-page":"938","DOI":"10.1158\/1541-7786.MCR-21-0029","volume":"20","author":"M Rahman","year":"2022","unstructured":"Rahman M, Olson I, Mansour M, Carlstrom LP, Sutiwisesak R, Saber R et al (2022) Selective Vulnerability of Senescent Glioblastoma Cells to BCL-XL Inhibition. Mol Cancer Res 20:938\u2013948. https:\/\/doi.org\/10.1158\/1541-7786.MCR-21-0029","journal-title":"Mol Cancer Res"},{"key":"5768_CR211","doi-asserted-by":"publisher","first-page":"973","DOI":"10.1038\/ncb1909","volume":"11","author":"F Rodier","year":"2009","unstructured":"Rodier F, Copp\u00e9 J-P, Patil CK, Hoeijmakers WAM, Mu\u00f1oz DP, Raza SR et al (2009) Persistent DNA damage signalling triggers senescence-associated inflammatory cytokine secretion. Nat Cell Biol 11:973\u2013979. https:\/\/doi.org\/10.1038\/ncb1909","journal-title":"Nat Cell Biol"},{"key":"5768_CR212","doi-asserted-by":"publisher","first-page":"1006","DOI":"10.1016\/j.cell.2008.03.038","volume":"133","author":"JC Acosta","year":"2008","unstructured":"Acosta JC, O\u2019Loghlen A, Banito A, Guijarro MV, Augert A, Raguz S et al (2008) Chemokine signaling via the CXCR2 receptor reinforces senescence. Cell 133:1006\u20131018. https:\/\/doi.org\/10.1016\/j.cell.2008.03.038","journal-title":"Cell"},{"key":"5768_CR213","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1007\/s11060-023-04387-3","volume":"164","author":"R Chojak","year":"2023","unstructured":"Chojak R, Fares J, Petrosyan E, Lesniak MS (2023) Cellular senescence in glioma. J Neurooncol 164:11\u201329. https:\/\/doi.org\/10.1007\/s11060-023-04387-3","journal-title":"J Neurooncol"},{"key":"5768_CR214","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.1016\/j.cell.2008.03.039","volume":"133","author":"T Kuilman","year":"2008","unstructured":"Kuilman T, Michaloglou C, Vredeveld LCW, Douma S, van Doorn R, Desmet CJ et al (2008) Oncogene-induced senescence relayed by an interleukin-dependent inflammatory network. Cell 133:1019\u20131031. https:\/\/doi.org\/10.1016\/j.cell.2008.03.039","journal-title":"Cell"},{"key":"5768_CR215","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1038\/s41419-025-07651-8","volume":"16","author":"C Schwarzenbach","year":"2025","unstructured":"Schwarzenbach C, Rinke J, Vilar JB, Sallbach J, Tatsch L, Schmidt A et al (2025) Therapy-induced senescence of glioblastoma cells is determined by the p21CIP1-CDK1\/2 axis and does not require activation of DREAM. Cell Death Dis Nat Publishing Group 16:357. https:\/\/doi.org\/10.1038\/s41419-025-07651-8","journal-title":"Cell Death Dis Nat Publishing Group"},{"key":"5768_CR216","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1038\/s44321-025-00201-x","volume":"17","author":"N Tomimatsu","year":"2025","unstructured":"Tomimatsu N, Di Cristofaro LFM, Kanji S, Samentar L, Jordan BR, Kittler R et al (2025) Targeting cIAP2 in a novel senolytic strategy prevents glioblastoma recurrence after radiotherapy. EMBO Mol Med 17:645\u2013678. https:\/\/doi.org\/10.1038\/s44321-025-00201-x","journal-title":"EMBO Mol Med"},{"key":"5768_CR217","doi-asserted-by":"publisher","first-page":"656","DOI":"10.1038\/nature05529","volume":"445","author":"W Xue","year":"2007","unstructured":"Xue W, Zender L, Miething C, Dickins RA, Hernando E, Krizhanovsky V et al (2007) Senescence and tumour clearance is triggered by p53 restoration in murine liver carcinomas. Nat Nat Publishing Group 445:656\u2013660. https:\/\/doi.org\/10.1038\/nature05529","journal-title":"Nat Nat Publishing Group"},{"key":"5768_CR218","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1038\/nature10599","volume":"479","author":"T-W Kang","year":"2011","unstructured":"Kang T-W, Yevsa T, Woller N, Hoenicke L, Wuestefeld T, Dauch D et al (2011) Senescence surveillance of pre-malignant hepatocytes limits liver cancer development. Nat Nat Publishing Group 479:547\u2013551. https:\/\/doi.org\/10.1038\/nature10599","journal-title":"Nat Nat Publishing Group"},{"key":"5768_CR219","doi-asserted-by":"publisher","first-page":"1149","DOI":"10.1016\/S1470-2045(10)70261-8","volume":"11","author":"WH Wilson","year":"2010","unstructured":"Wilson WH, O\u2019Connor OA, Czuczman MS, LaCasce AS, Gerecitano JF, Leonard JP et al (2010) Navitoclax, a targeted high-affinity inhibitor of BCL-2, in lymphoid malignancies: a phase 1 dose-escalation study of safety, pharmacokinetics, pharmacodynamics, and antitumour activity. Lancet Oncol Elsevier 11:1149\u20131159. https:\/\/doi.org\/10.1016\/S1470-2045(10)70261-8","journal-title":"Lancet Oncol Elsevier"}],"container-title":["Journal of Neuro-Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11060-026-05768-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11060-026-05768-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11060-026-05768-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T20:02:55Z","timestamp":1791403375000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11060-026-05768-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,26]]},"references-count":219,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["5768"],"URL":"https:\/\/doi.org\/10.1007\/s11060-026-05768-0","relation":{},"ISSN":["0167-594X","1573-7373"],"issn-type":[{"value":"0167-594X","type":"print"},{"value":"1573-7373","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,26]]},"assertion":[{"value":"21 July 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 August 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 August 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","label":"Ethics approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":3,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"ABH serves on the advisory board of Caris Life Sciences, Immunogenik, and the WCG Oncology Advisory Board, holds stock and stock options in Caris Life Sciences, and is supported by research grants from Alnylam and AbbVie. Immunogenik holds rights related to the CD70 CAR T-cell platform.","order":4,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"55"}}